Document:

EX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

MASTER PURCHASE AGREEMENT 

between 
 MEVION MEDICAL
SYSTEMS, INC. 
 and 

STORRINGTON INDUSTRIES LIMITED 

AGREEMENT 
 This Master Purchase
Agreement (this “Agreement”) is entered into as of May 10, 2012 (the “Effective Date”) by and between Mevion Medical Systems, Inc., a Delaware corporation with a business address of 300 Foster Street, Littleton,
Massachusetts 01460 (“BUYER”), and Storrington Industries Limited, a UK corporation, with a business address of Unit 1, Water Lane, Storrington, RH20 3EA, United Kingdom (“SELLER”). 

WHEREAS, BUYER and SELLER are parties to that certain Sale and Purchase Agreement (dated December 5, 2007) (the “Existing Agreement”); pursuant
to which BUYER has agreed to purchase from SELLER, and SELLER has agreed to manufacture and sell to BUYER, certain products described in the Existing Agreement; 

WHEREAS, the parties wish to terminate the Existing Agreement and enter into this Agreement pursuant to which BUYER shall purchase from SELLER a varying
number of Products (as defined below), and SELLER shall sell to BUYER such ordered Products; and 
 WHEREAS, the parties wish to establish in this Agreement
the detailed terms and conditions under which BUYER shall purchase from SELLER the Products. 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereby agrees as follows: 
 1. TERM 

The term of this Agreement shall commence on the Effective Date and continue for a period of sixty (60) months (the “Initial Term”), unless
earlier terminated as provided herein. After the Initial Term, this Agreement shall automatically renew on the terms and conditions contained herein for additional twenty four (24) month periods (each, a “Renewal Term” and together
with the Initial Term, the “Term”), unless a party notifies the other party of its intent not to renew at least [***] prior to the beginning of a Renewal Term. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 2. ORDER OF PRECEDENCE 

In the event of any conflict of terms, the following controlling priorities shall apply: 

2.1 This Agreement, as may be amended from time to time in accordance with the provisions hereof. 

2.2 Each Statement of Work that may be issued under this Agreement. 

2.3 Any attachment or addendums to this Agreement, except to the extent that the attachment or addendum expressly supersedes the subject
matter in question. 
 2.4 Any Purchase Order issued hereunder hereto. 

3. SUPPLY; STATEMENTS OF WORK 

3.1 BUYER hereby engages SELLER to manufacture and supply products pursuant to one or more Statements of Work (each a “Product,” and
collectively, the “Products”) in accordance with the applicable Statement of Work and in compliance with the terms and conditions set forth in this Agreement, and SELLER hereby accepts such engagement. 

3.2 The first Statement of Work is attached hereto as Exhibit A-1 and the Product described therein is referred to herein as the
“System.” With respect to any new Product to be governed by this Agreement, a new Statement of Work shall be added to Exhibit A after execution by the parties of a written Statement of Work. There shall be no limit to the number of
Statements of Work that may be added to Exhibit A and governed by the terms and conditions of this Agreement. 
 3.3 Each
Statement of Work shall include a description of the services to be provided, including, if applicable, the Product to be manufactured, relevant specifications for the deliverables (“Specifications”), a corresponding budget, a schedule for
completion of services described in the Statement of Work (which may be set forth for the entire Statement of Work or stages thereof), as well as a Purchase Order outlining the agreed upon fee and payment schedule, delivery terms, and such other
information as the parties determine is necessary for SELLER to perform the services and manufacture and supply the Product (the “Purchase Order”). The form of the Purchase Order is attached hereto as Exhibit A-2. 

3.4 SELLER guarantees that it can and shall supply BUYER with the quantity of Products that are ordered by BUYER (a) in accordance with
the lead times and delivery schedule set forth in the Statement of Work, (b) pursuant to Purchase Order(s) which contain BUYER’s part number, a part description, the per unit Purchase Price (as defined below), quantity, delivery date, and
mode of transport issued hereunder and accepted by SELLER during the Term, and (c) issued in accordance with the forecasts issued by BUYER in accordance with Section 6. If BUYER issues a Purchase Order or Purchase Orders for a quantity of
Products that exceeds the number of Products specified in BUYER’s forecasts or the delivery schedule set forth in the 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
Statement of Work, SELLER shall notify BUYER within [***] if SELLER is unable or unwilling to supply such excess quantities to BUYER. If SELLER does not notify BUYER of any discrepancies on a
Purchase Order received by SELLER within [***] of receipt thereof; such Purchase Order(s) shall be deemed to have been accepted by SELLER. SELLER shall accept Purchase Orders that are issued by BUYER in accordance with BUYER’s forecasts and the
other terms and conditions of this Agreement. 
 3.5 SELLER shall deliver to BUYER only the quantity of Products authorized by BUYER’s
Purchase Orders. Other than as set forth in Section 6 below, BUYER shall not be liable for any expenses incurred by SELLER with respect to any Products unless a Purchase Order has been issued by BUYER and accepted by SELLER. 

3.6 If any material used to make products is provided to SELLER by BUYER, BUYER must provide that material on the date required by SELLER. For
each day such material is delivered late by BUYER, the Delivery Date (as defined below) for the Products that are to incorporate such materials shall be extended by one day. 

3.7 In situations where either party provides materials or supplies to SELLER in connection with this Agreement and/or a Statement of Work
(s) (excluding Products purchased by BUYER hereunder), such receiving party shall use such materials and supplies only in accordance with the applicable Statement of Work for which it was received, and such receiving party shall not use it for
any other purpose. The receiving party shall be responsible for all such materials and supplies provided by the providing party while they are in the receiving party’s control or the control of its agents, and the receiving party shall
promptly, at the providing party’s direction, destroy or return to the providing party all unused quantities of materials and supplies provided by the providing party. If any materials or supplies provided by BUYER are destroyed or damaged by
SELLER as a result of SELLER’s negligence or intentional misconduct, then SELLER shall be responsible for replacing the destroyed or damaged materials or paying BUYER the replacement value of the damaged or destroyed materials and any costs or
expenses to accelerate the supply chain for such materials or supplies. For the avoidance of doubt, each party shall retain title to all materials and supplies while they are in the other party’s facility. 

4. EXCLUSIVITY 
 4.1 SELLER
agrees to manufacture and supply Exclusive Products (as defined below) exclusively to BUYER, as and when BUYER may order the same, pursuant to the terms and conditions of this Agreement and any applicable Statements of Work. During the Term and for
[***] thereafter, SELLER agrees not to manufacture or supply any Exclusive Product for itself, for any of its affiliates, or for any third party, or to manufacture, sell or supply any Exclusive Product to any third party without BUYER’s prior
written consent. For the purposes of this Section 4.1, “Exclusive Products” means superconducting magnets for synchrocyclotrons for proton therapy. Notwithstanding the foregoing, the exclusivity restrictions set forth in this
Section 4.1 shall terminate if BUYER: (a) fails to take delivery of the Minimum System Quantities (as defined below) [***], and such failure is not due to SELLER’s failure to perform its obligations hereunder; or (b) BUYER is in
material default of this Agreement and BUYER fails to cure such default within [***] of BUYER’s receipt of written notice of such default from SELLER. “Minimum System Quantities” means [***]. 

  
 3 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 4.2 During the term of this Agreement and subject to the provisions of Section 4.3
below, BUYER shall not outsource or secure from any other vendor the Exclusive Products. BUYER agrees that Seller shall be the exclusive supplier of the Exclusive Products aside from provisions below for partial supply by BUYER. 

4.3 Subject to BUYER having sufficient orders for Mevion S250 systems to support BUYER’s purchase of the Minimum System Quantities, BUYER
agrees to purchase the Minimum System Quantities from SELLER. In addition, during the Term and subject to the remainder of this Section 4.3, BUYER agrees to purchase Systems exclusively from SELLER, and not to manufacture Systems for sale nor
have Systems manufactured by a third party. Notwithstanding the foregoing, the exclusivity restrictions set forth in this Section 4.3 shall terminate if (a) SELLER fails to deliver any Product within [***] following the applicable Delivery
Date for such Product, (b) [***] or (c) SELLER is unable or unwilling to supply the Minimum System Quantities. In addition, the exclusivity restrictions set forth in this Section 4.3 shall not apply with respect to Systems in excess
of the Minimum System Quantities, if BUYER has forecasted such excess Systems and SELLER has notified BUYER of Seller’s inability or unwillingness to provide such excess Systems. For the avoidance of doubt, nothing herein shall restrict BUYER
from developing internal manufacturing capabilities for System so that BUYER is capable of manufacturing Systems in the event the exclusivity restrictions herein do not prohibit such manufacture. In the event that (a) BUYER has not been
relieved of its exclusivity obligations set forth in Section 4.3, and (b) BUYER delivers a MEVION S250 to a customer which includes a superconducting magnet system that was manufactured by BUYER (and not by SELLER), BUYER agrees to pay to
SELLER a fee of $[***] for each such delivered MEVION S250 (the “Magnet Manufacturing Fee”). The payment obligations set forth in this Section 4.4 shall terminate upon the earlier to occur of (i) the date that BUYER pays to
SELLER $[***] of aggregate Magnet Manufacturing Fees hereunder, (ii) the date that BUYER has purchased the Deposit Materials in accordance with Section 18, and (iii) expiration or termination of this Agreement. 

4.4 BUYER shall maintain accurate shipping records in sufficient detail to permit the identification of superconducting magnet systems
manufactured by BUYER for which a Magnet Manufacturing Fee is payable. Upon reasonable prior written notice to BUYER, an independent accountant selected by SELLER and reasonably acceptable to BUYER and not paid in whole or in part by a contingent
fee arrangement, shall have reasonable access during normal business hours, but not more often that once in any calendar year, to BUYER’s shipping records as may reasonably be necessary to conduct a review for the purpose of verifying the
accuracy of BUYER’s payment of Magnet Manufacturing Fees hereunder. Prior to commencing any such inspection, the accountant shall enter into a reasonable and customary confidentiality agreement with BUYER which prohibits the disclosure of any
information, except as provided in said confidentiality agreement, relating to BUYER to any person or entity, except that such accountant may issue a report to SELLER, the sole purpose of which shall be to report to SELLER whether BUYER complied
with the payment provisions of Section 4.5 above. 

  
 4 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 5. PURCHASE PRICE 

5.1 Pricing 
 SELLER shall sell the Products to
BUYER at the purchase prices set forth on the applicable Statement of Work (as such prices may be adjusted hereunder, “Purchase Price(s)”). [***] Upon BUYER’s receipt of such proposal, the parties shall promptly discuss in good faith
an equitable adjustment to the Purchase Price. In the event the parties are unable to agree to such adjustment, the matter shall be addressed in accordance with the arbitration provision set forth in Section 22.5. The adjusted prices shall be
effective as set forth in Section 5.4. Purchase Prices shall be honored by SELLER for delivery to all BUYER sites or locations, and if authorized by BUYER, to any BUYER-authorized subcontractors or customers. 

5.2 All-Inclusive 
 The Purchase Price for each
Product shall be all-inclusive and represents the sole and exclusive consideration to SELLER hereunder for the Products or otherwise, except for [***]. BUYER shall not be billed for, nor shall BUYER have any obligation to pay, any charge or amount
not specifically authorized in BUYER’s duly issued Purchase Order. Any additional terms or conditions contained on any SELLER invoice, packing slip or other SELLER documentation shall not be binding on BUYER, and no action by BUYER (including
the payment of any such invoice in whole or in part) shall be construed as binding BUYER with respect thereto. 
 5.3 Taxes 

[***] 
 5.4 Effective Date of Purchase Price
Changes 
 All changes in Purchase Prices shall be effective only for new Purchase Orders for Products. 

5.5 Process Improvement 
 The parties shall
jointly manage process improvements for the manufacturing process for the Products. The parties shall conduct an annual review for material and labor cost reductions, lead time reduction, and inventory reduction, and SELLER shall keep a material and
labor cost breakdown containing all particulars that may be necessary for the purpose of performing such reviews. The parties shall make appropriate personnel available for such annual review, including operations management, procurement, and
planning resources for such party. Changes identified through the annual review process shall be handled as part of SELLER’s ECR (defined below) process and as further set forth in Section 3. 

  
 5 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 5.6 Cost Reduction Allocation 

SELLER agrees to seek commercially reasonable ways to reduce the cost of manufacturing Products by methods such as reduction of materials costs and component
costs and improvements in procurement, production processes and labor efficiency (“Manufacturing Cost Reductions”). In the event that Manufacturing Cost Reductions are achieved by SELLER, including without limitation through Value
Engineering (V/E) efforts or through the process improvement review procedures set forth in Section 5.5, the then Purchase Price for the applicable Product shall, on a going-forward basis, be decreased by an amount equal to [***]. SELLER shall
promptly disclose all Manufacturing Cost Reductions to BUYER. 
 6. SYSTEM FORECASTS and CONFIRMED FIRM PURCHASE ORDERS 

6.1 As soon as practicable after the Effective Date and on or prior to the first business day of each calendar quarter thereafter, BUYER shall
provide SELLER with [***] rolling forecasts of BUYER’s anticipated requirements of Systems covering the [***] period commencing on the first business day of the calendar quarter following the day on which such forecast is provided by BUYER to
SELLER. 
 6.2 The first [***] of each forecast (the “Confirmed Firm Order Period”) shall be binding on BUYER. BUYER shall issue
Purchase Orders for each System within the [***] lead time for Systems. As part of the forecast and firm order detail issued quarterly, BUYER shall confirm the orders already specified for delivery during the Confirmed Firm Order Period, and
reconcile those firm orders in the second quarter of the Confirmed Firm Order Period to the previously forecast Systems. 
 6.3 In each
forecast following the initial forecast, BUYER may increase or decrease the aggregate quantity of Systems specified for delivery during the [***] of the forecast (The “Mid-Term Forecast Period”) from the amount set forth in corresponding
calendar period in the immediately preceding forecast by a net total of one System without incurring any penalty or additional liability hereunder. In the event that BUYER decreases the net quantity of Systems set forth in the Mid-Term Forecast
Period of a forecast by [***] Systems from the quantity forecasted for corresponding period in the immediately preceding forecast, BUYER agrees to pay to SELLER a rescheduling fee of [***] (the “Rescheduling Fee”) for [***]. In the event
that BUYER increases the aggregate quantity of Systems specified for delivery during the Mid-Term Forecast Period by [***] over the amount set forth for the corresponding calendar period in the immediately preceding forecast, SELLER shall use
commercially reasonable efforts to provide, but shall not be obligated to provide, such excess quantities of Systems. 
 6.4 The quantity of
Systems set forth in a forecast for the period following the Initial and Mid-Term Forecast Period [***] (the “Long Term Forecast Period”) shall be non-binding estimates only and BUYER shall have no obligation to purchase the quantity of
Systems forecast for the Long Term Forecast Period. 

  
 6 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 6.5 Rescheduling Purchase Orders 

Within [***] of the scheduled delivery date for a Product as set forth in the BUYER’s Purchase Order (the “Delivery Date”), but prior to the
date that the SELLER has shipped such Product, BUYER may, free of charge and once per each such Product, reschedule the Delivery Date by delivering notice to Seller (delivered electronically, by facsimile, or by mail) to another date that is within
[***] following the original Delivery Date. Rescheduling the delivery of a Product to a date that is earlier than the Delivery Date set forth in the Purchase Order is subject to SELLER’s written consent. The new Delivery Date specified in
BUYER’s notice (or as agreed to by SELLER, if the proposed rescheduled date is earlier than the Delivery Date set forth in the Purchase Order) shall then become the new Delivery Date for the applicable Product, and the Purchase Order shall in
all other respects remain in full force and effect. 
 7. PAYMENT TERMS 

7.1 Invoices 
 SELLER shall invoice BUYER for the
Purchase Price of the Products at the time of shipment or as otherwise set forth in the Purchase Order, and BUYER shall pay invoices as set forth herein. 

7.2 Payment 
 Payment for invoices issued in
accordance with the terms hereunder shall be due within [***] after receipt of the invoice without any deduction, set-off or counterclaim, except as expressly provided herein. All Purchase Prices shall be paid in U.S. dollars. 

8. PACKAGING, SHIPPING AND FREIGHT 

8.1 Delivery Definition 
 Delivery of a Product
shall occur upon BUYER’s physical receipt of such Product at the Delivery Destination. SELLER shall cause all Products to be delivered to the Delivery Destination per the Delivery Date Schedule in Sections 6.1 and 6.2 and shall also comply with
any special shipping instructions provided by BUYER. 
 8.2 Packing Requirements 

All Products shall be prepared, marked and packed for shipment in accordance with the packing instructions attached as Attachment I. SELLER shall
assure packaging is adequate to protect Product from damage during shipping to BUYER location. SELLER shall comply with BUYER’s requirements for information to be included on packing slip and invoice as detailed in Attachment II.

 8.3 Terms of Sale 
 All
Products shall be provided FOB Nazareth, PA or equivalent East Coast US address (during the interim when the PA stock location is not filled,Incoterms 2010). 

  
 7 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 8.4 Delivery Date Change Notification 

SELLER shall immediately notify BUYER of any event or condition that could change or delay delivery of the Products from the scheduled Delivery Date. 

8.5 Excess, Early and Late Deliveries 
 BUYER
shall not be obligated to accept or pay for: (i) any Products in excess of the quantity ordered in its Purchase Order (“Excess Product(s)”), (ii) deliveries arriving more than [***] in advance of the Delivery Date specified on
the Purchase Order (“Premature Product(s)”), or (iii) deliveries arriving more than [***] later than the Delivery Date specified on the Purchase Order (provided that such Purchase Order is issued in accordance with the required lead
times set forth in the Statement of Work and such delay is not directly caused by BUYER) (“Late Products”). Notwithstanding the foregoing, if BUYER does accept delivery, BUYER shall be obligated to pay for such Product in accordance with
Section 7, provided that BUYER shall be entitled to [***] reduction of the Purchase Price for any Product for each [***] period that the Product is delivered late, as applicable up to a maximum reduction of [***] per Product, as applicable.
There shall be no penalty for Premature Products however BUYER shall not process the receipt until [***] before the Delivery Date. 
 8.6
Delivery Lead Times 
 Subject to Section 19, the delivery lead time for all Products purchased under this Agreement shall be governed by those lead
times noted in the applicable Statement of Work for such Products. SELLER shall work with BUYER to continue to reduce lead time. 
 8.7
International Trade Compliance 
 SELLER understands and agrees that all articles of foreign (i.e. not the United States) origin imported into the United
States must be marked with the English name of the country of origin of the articles in a conspicuous location, as legibly, indelibly and permanently as the nature of the article shall permit. The purpose of these laws is to inform the U.S.
“ultimate purchaser” of the country of origin. 
 For all articles of foreign origin, a commercial invoice must be properly filled out and
submitted in the form agreed to by the parties. 
 9. TITLE AND RISK OF LOSS 

Title to Products shall pass to BUYER when the invoice is paid in full. The risk of loss and damage to Products passes to BUYER in accordance with DDP
(INCOTERMS 2010) (i.e., the Products are placed at the disposal of the BUYER at the destination set forth in the Purchase Order.). SELLER shall convey title to all Products to BUYER free and clear of all liens, encumbrances, security interests,
claims, and other interests whatsoever. 

  
 8 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 10. SELLER SAFETY STOCK 

10.1 In the event that BUYER is capable of supplying SELLER with sufficient conductor material for SELLER to manufacture [***] (each, a
“Surplus System”), BUYER shall promptly notify SELLER of same. BUYER shall supply such conductor material to SELLER, and SELLER shall manufacture the Surplus Systems at SELLER’s expense in accordance with a schedule to be discussed
and agreed upon by the parties in good faith. Following completion of the manufacture of the first Surplus System, SELLER shall ship such Surplus System, at SELLER’s expense, along with a complete set of drawings, manufacturing documents and
other data and information that are at least sufficient to enable a reasonably skilled manufacturer in the trade to manufacture Systems [***] (including part drawings, bills of material, assembly, test, and inspection process travelers and data
collection forms) (the “System Manufacturing Information”), to the facility of SELLER’s wholly owned subsidiary, Everson Tesla Incorporated (“Everson Tesla”), located at Everson Tesla Incorporated, 615 Daniels Road,
Nazareth, PA 18064. SELLER shall be solely responsible for storage costs and risk of damage and loss of the Surplus System while in transit to and stored at Everson Tesla’s facility. The second System manufactured pursuant to this
Section 10 shall be stored in a suitable container at SELLER’s manufacturing facility located at Unit 1, Water Lane, Storrington, RH20 3EA, United Kingdom. Nothing in this section shall preclude Tesla and Mevion from mutually agreeing to
supply conductor and produce cold masses or systems in addition to the two safety stock in order to maximize efficiency of the production process. 

10.2 Production of Surplus Systems is of secondary importance to production demands, and shall be done without impacting the System production
and/or delivery schedule. Notwithstanding the foregoing, the Surplus Systems will be utilized by BUYER on a first in, first out basis as follows. Provided there is a Surplus System at the Everson Tesla Facility in Nazareth, PA, the BUYER shall take
delivery of a regularly forecasted system from that location. SELLER shall replace that system with a system already in stock at SELLER’s facility in StorrmgtoiLUK. SELLER shall then replace the Surplus System at the Storrington location in no
more than [***] to provide for the balance of [***] Surplus Systems to continue. SELLER shall organize production and BUYER shall supply sufficient conductor to enable the first surplus system to be available in Nazareth, PA within one year of
signing this agreement. 
 10.3 Notwithstanding the foregoing, SELLER’s obligations with respect to maintenance of Surplus Systems
shall terminate as set forth in Section 17. 
 11. MODIFICATION OF PRODUCTS 

11.1 BUYER shall have ultimate affirmative and negative control of design changes. SELLER shall implement any design change requested by BUYER
within ninety (90) days, with the SELLER having opportunity to re-quote if there is a change in the Product’s manufacturing cost. Any design change proposed by SELLER for Products supplied hereunder shall be sent to BUYER for prior review
and approval before implementation. The parties agree to jointly review any proposed design change within [***] after receipt of such proposal. Changes shall be communicated using SELLER’s Engineering Change Request (ECR) process which is
attached 

  
 9 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
hereto as Attachment V. In the event that either SELLER or BUYER requests a design change to a Product and SELLER reasonably determines that, as a result of such design change, an adjustment is
required to the proposed delivery schedule set forth in a Purchase Order or Statement of Work, as applicable, the parties shall discuss in good faith, agree on such adjustment and modify the Purchase Order or Statement of Work, as applicable,
accordingly. 
 11.2 SELLER shall not change material, components, manufacturing process, dimensions, tolerances, or specifications for the
Products without prior written consent of BUYER, which consent shall not be unreasonably withheld. In all cases, SELLER shall provide BUYER with at least [***] written notice (or such longer period as agreed to by the parties) in advance of
SELLER’s proposed implementation of any modification, and shall continue to manufacture unmodified Products until such time as BUYER approves of the proposed change. BUYER retains sole discretion to accept or reject proposed design changes. For
the purposes of this Agreement, a Product shall be “compatible” if it shall continue to perform all significant functions of the Product before such modification when used in conjunction with Existing Systems, without any modification to
such Existing Systems. SELLER shall assure that all Products that are modified after the Effective Date (“Modified Product(s)”) shall be “compatible” (as defined herein) in such modified form with all hardware and software
utilized by BUYER in conjunction with such Modified Products (including monitoring software) prior to the modification thereof (collectively, “Existing Systems”). 

11.3 Notwithstanding Section 11.2, if a supplier of SELLER is no longer able or willing to supply to SELLER materials or components as
the case may be, SELLER shall notify BUYER of the same and SELLER shall be permitted to secure a different supplier with the consent of the BUYER, which consent shall not be unreasonably withheld. 

12. QUALITY INSPECTION AND ACCEPTANCE OF INCOMING PRODUCT 

12.1 Shipping Condition 
 SELLER shall ship all
Products to BUYER in new condition. SELLER shall fill each Purchase Order in accordance with its terms and the provisions hereof, except as otherwise expressly provided herein 

12.2 Inspection; Acceptance 

(a) Before shipping any Product, SELLER shall test the Product in accordance with testing and quality assurance procedures to
be mutually agreed to by the parties in writing (the “Testing Procedures”) to ensure that such Product is free from defects and conforms to the applicable Specifications. Any Product that is not free from defects or does not conform to the
applicable Specifications is referred to herein as a “Defective Product.” SELLER shall notify BUYER [***] of performing any Testing Procedures so that a BUYER representative has the opportunity to be present at SELLER’s facility to
observe such Testing Procedures. At or before shipment of any Product, SELLER shall furnish the BUYER with a certificate, in form and substance 

  
 10 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
reasonably satisfactory to the BUYER, to the effect that SELLER has performed the Testing Procedures on such Product and did not identify any defects or nonconformities to the Specifications
(“Initial Acceptance”). If the Testing Procedures establish that the Product is a Defective Product, BUYER may (i) elect to take delivery of the Product and equitably reduce the Purchase Price by a mutually agreed upon amount [***];
or (ii) require SELLER to promptly replace or correct the Defective Product. SELLER shall document a corrective action for all rejected Defective Products. For any Defective Products that are manufactured using BUYER provided materials or
supplies, SELLER is responsible for reimbursement of BUYER, or recovering the BUYER materials or supplies in a method to be approved by BUYER. BUYER agrees that there will be no hold-back from any future payments for a Product regarding a prior
Defective Product. 
 (b) Upon receipt of a Product, BUYER shall have a period of up to [***] from shipment to test (through
installation, inspection, or use thereof) the Product to confirm that such Product, as delivered, is free from defects and conforms to the applicable Specifications. BUYER shall notify SELLER as soon as practicable whether or not such Product is
free from defects and conforms to the applicable Specifications. If BUYER tests the Product during such [***] period, “Final Acceptance” shall be deemed to occur when (i) BUYER’s delivery of notice to SELLER confirming that the
PRODUCT complies with the Specifications, (ii) or, if BUYER reasonably determines that the Product does not conform to the Specifications, the date that such non-conformity is remedied pursuant to Section 13.2. If, however, BUYER does not
test the PRODUCT during such [***] period, or does not notify SELLER that such PRODUCT does or does not conform to the Specifications during such [***] period, “Final Acceptance” shall be deemed to have occurred upon the expiration of such
[***] period. For the avoidance of doubt, no testing, inspection or other action by the BUYER shall in any way derogate from SELLER’s warranties or BUYER’s remedies set forth herein with respect to such Product. 

(c) BUYER and SELLER shall mutually agree to a detailed Device Master Record (DMR) and documentation for each Product,
including, without limitation, a series of in-process tests for each Product, and hold points in manufacturing of the Product to allow for BUYER review and approval of in-process test results. BUYER shall be permitted to view in-process tests, but
shall be strictly prohibited from copying or removing any information except as required by law or regulation, and after notice to SELLER with the opportunity of SELLER to ascertain if such law or regulation requires the copying or removing of such
information. For purposes of this Agreement, “DMR” shall mean (i) manufacturing process development for Product; (ii) all manufacturing and control procedures necessary for the manufacturing, testing and quality control release
of Product; and (iii) sourcing and testing of all raw materials and components used in the production of any Product. As reasonably required by BUYER in connection with Product manufacturing activities hereunder, SELLER shall enter into a
written quality agreement with BUYER. 

  
 11 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 (d) BUYER and its agents and designees shall have the right to audit
SELLER’s facilities, systems, records, procedures, and documentation related to this Agreement and any Statement of Work. In connection with any such audit, SELLER shall also provide BUYER reasonable access to its personnel. Such audits may be
conducted upon reasonable notice during the Term and for a period of up to [***] after termination or expiration of this Agreement, or for such longer period as may otherwise be required under applicable laws. If requested by BUYER, and provided
that the exclusivity described in Section 4.1 is still applicable, SELLER shall permit and provide working space for BUYER to staff persons on location at SELLER’s premises during preparation for manufacturing and packaging. Such persons
shall be given reasonable access to all records, facilities and personnel working on any Statement of Works, including, without limitation all quality and manufacturing process documentation including part specifications, part drawings, assembly
drawings, bills of material, assembly instructions (travelers), test procedures, test fixtures, and training records. BUYER’S rights hereunder are specifically limited to the right to audit and shall not include any right to copy or remove
information except as required by law or regulation. BUYER’S personnel will only be given access to records and other data in the presence of SELLER’s personnel. BUYER shall not be restricted from note taking as long as the resulting
records are maintained in accordance with the confidentiality provisions included below. 
 12.3 Quality Assurance 

SELLER shall establish process controls, ongoing inspection and test procedures such that the Products manufactured meet the required quality level agreed
upon by BUYER and SELLER. SELLER agrees that it shall, at all times during the Term, maintain an ISO 13485 certified medical device manufacturing facility. 

13. PERFORMANCE WARRANTY 

13.1 Performance Warranty 
 To the extent
provided in this Section 13, SELLER warrants solely to BUYER the good quality of each Product and Spare Part (as defined in Section 13.2) sold by it to BUYER and that such Product and Spare Part complies with and performs in accordance
with the Specifications -except non conformities accepted by BUYER in writing—and shall be free from defects in materials or workmanship. The warranty covers parts, materials and labor provided by SELLER, and does not include parts, materials
and labor provided by BUYER. SELLER shall not be responsible for any warranty obligations caused by a failure of parts or material provided by BUYER. 

  
 12 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 13.2 Warranty Obligations 

During a period of [***] from the date of delivery to BUYER, or [***] after installation at a customer site, whichever is earliest, SELLER shall supply to
BUYER, free of charge, replacements of such Part(s), sub-assemblies, or Products as have proved to have such defects as set out above (collectively, “Spare Parts”) or, at BUYER’ option after discussing in good faith with SELLER,
repair such Parts, sub-assemblies, or Product(s) at SELLER’s cost, or have them repaired at SELLER’s order and expenses and after mutual agreement with BUYER through BUYER’ service personnel at SELLER’s cost, it being understood
that all reasonable costs connected with the forwarding of such Parts, sub-assemblies and/or Product(s) to SELLER for replacement or repair and from SELLER of the new or repaired Parts, sub-assemblies and/or Products shall be for the account of
SELLER. Notwithstanding the above, any expenditure of the BUYER which the BUYER seeks reimbursement from the SELLER must first be approved in writing by the SELLER. Replaced Products, sub-assemblies and Parts shall become the property of SELLER and
shall on SELLER’s request be returned to it at its cost. With respect to electronic components, the warranty period shall be [***] from the date of delivery to BUYER. With respect to Spare Part(s), the warranty period shall be [***] from the
date of delivery to BUYER, which may be reduced for certain parts if the shelf life, useful life or design life is demonstrated by SELLER based upon objective criteria to be less than such [***] period. 

13.3 Conditions 
 This Product warranty is
subject to BUYER promptly notifying SELLER in writing of the failure as it appears to BUYER, making available within a reasonable interval a written report of the defect or failure including description of the circumstances where under the defect or
failure appeared, (to the extent BUYER is capable of providing such information) and access to the Product. 
 13.4 Limitations 

THE FOREGOING WARRANTIES AND THOSE IN THIS SECTION 13 ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY OR FITNESS
FOR A PARTICULAR PURPOSE. 
 Such warranties shall not apply to the extent a defect is caused by any of the following circumstances: (a) BUYER’s
customer has not maintained and operated the Product in accordance with SELLER or BUYER manuals (b) the Product is improperly stored, (c) the Product is misused or abused, (d) Product is modified or repaired by a party other than
SELLER or SELLER’s authorized representative or as otherwise agreed by SELLER in writing, (e) the failure is caused by transportation after title passes to BUYER, provided always that SELLER can reasonably provide evidence that the
malfunctioning or damage is caused by non observance of any of the provisions under a-e, and would otherwise not have occurred. In the event that SELLER repairs a product which is not covered by warranty due to operation of this Section 13.4,
SELLER may at its discretion, offer a warranty on the product so repaired. 
 THE ABOVE UNDERTAKINGS AND THOSE SET FORTH IN THIS SECTION 13 STATE
SELLER’s ENTIRE LIABILITY WITH RESPECT TO WARRANTY DEFECTS OF FAILURES, AND SELLER SHALL NOT BE LIABLE FOR ANY SPECIAL OR CONSEQUENTIAL DAMAGES IN CONNECTION THEREWITH. 

  
 13 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 13.5 Epidemic Faults 

Under this warranty SELLER warrants to BUYER that Product and Spare Parts shall be free of epidemic faults (class failures). Epidemic faults are for the
purpose of this Agreement defined as defects which are the same or have the same origin with a class failure quantity of [***] Products within a maximum period of [***] from the delivery date of the last of the [***] Products. [***] In case of such
epidemic faults, SELLER, after the initial warranty period in accordance with Section 13.2, warrants solely that the Products or relevant Parts not yet delivered shall be upgraded, and for all Products and Parts already delivered upgraded
components or Products and Parts shall be available from SELLER free of charge and BUYER shall be responsible for the building in and building out of said components, as far as reasonably may be expected. In case said faults compromise the
certification of the Product to safety standards in effect at the time the Product was delivered or in case said faults endanger persons, SELLER shall bear the costs for the building in and building out of said components as well. Notwithstanding
the above, SELLER shall not be responsible for any Epidemic Faults caused by any parts or material supplied by BUYER. 
 13.6 Fit for
Purpose 
 SELLER warrants that the Products and Spare Parts shall be free from defects in design, material and workmanship, shall meet all Specifications,
and shall be fit and serviceable for the purpose intended for a period as described in Section 13.2. 
 14. INDEMNITY AND INSURANCE

 14.1 Indemnity. 
 SELLER shall be solely
liable for, and shall defend, indemnify, and hold BUYER, and its directors, officers, employees, agents, and independent contractors (all of the foregoing entities and individuals being collectively referred to herein as the “BUYER
Indemnitees”) harmless from and against any and all claims, causes of action, suits, damages, liabilities, injuries, losses, and costs (including reasonable attorneys and experts fees at trial and on appeal), and expenses (collectively,
“Liability”) which may be incurred by, asserted against, or recoverable from any BUYER Indemnitee to the extent arising out of or relating to any of the following: 

(a) the acts or omissions (whether negligent, reckless, intentional, or otherwise) of SELLER, its employees, agents, or
independent contractors related to the manufacture, performance and operation of the Product; 
 (b) any claim by a third
party that a Product, or the use, distribution, and resale thereof by BUYER, infringes upon, misappropriates, or violates any patent, copyright, trade secret, trade name, trademark, or any other proprietary right of a third party (other than to the
extent that such third party claim arises out of specifications provided by BUYER, for which BUYER shall indemnify SELLER); 

  
 14 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 (c) the Products or any defect therein (whether in design, materials,
workmanship, or otherwise), including any products liability claim and all claims based on strict liability in tort; or 

(d) any breach of this Agreement by SELLER, excluding late delivery, and including any breach, falsity, or inaccuracy of or in
any representation, warranty, obligation, or covenant of SELLER hereunder; and 
 (e) Any damages, penalties, fines,
attorney’s fees, or other losses of whatever kind or nature resulting from, or arising out of, any violations by SELLER or its employees, agents, or independent contractors of any applicable laws, rules or regulations governing international
transactions or activities including, but not limited to, export controls, import controls, customs regulations, trade embargoes and other trade sanctions, and laws governing unlawful boycotts and payments to foreign government officials. 

14.2 Insurance. 
 Throughout the Term, SELLER
shall maintain the following coverage’s with insurance companies with a Best’s rating of A- or above: 
 (a)
Employers liability insurance for damages and claimants costs and expenses in respect of bodily injury, death, disease, illness or nervous shock to any employee arising during the course of the business, up to a value of $[***] for any one claim or
series of claims arising out of anyone cause. 
 (b) General Liability, including blanket contractual and products liability,
with minimum limits of $[***] per occurrence, $[***] aggregate; 
 (c) Commercial Automobile Liability Insurance with limits
of liability not less than $[***] for bodily injury and property damage (the Commercial Automobile Liability coverage shall include coverage for all owned, leased, non-owned and hired automobiles); 

(d) Umbrella Liability with a limit of liability of not less than $[***] each occurrence and in the aggregate, combined single
limit for bodily injury and property damage (the Umbrella Liability Policy shall be in excess of the General Liability, Commercial Automobile Liability, and Employer’s Liability coverage’s and must include a per project annual aggregate).

 The insurance policies and certificates required by this Agreement shall contain a provision that coverage shall not be non-renewed, materially changed,
canceled or allowed to expire until at least [***] prior written notice has been given to BUYER. Such policies shall provide that the insurance provided for therein shall be primary insurance over any other valid and collectible insurance that the
additional insured may have with respect to a loss arising out of SELLER’s operations, and that other insurance of any additional insured applicable to a loss is excess over the obligations under said policy, and that the carrier’s
liability under said policy shall not be reduced by the existence of such other insurance. 

  
 15 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 15. ASSIGNMENT AND SUB-CONTRACTING 

SELLER shall not assign nor sub-contract its obligations under this Agreement, without the prior written consent of BUYER, provided that SELLER may procure
components for the Products from Third Parties. BUYER shall be permitted to assign this Agreement to any Affiliate or in the event of a merger, acquisition, reorganization, consolidation or sale of all or substantially all of its assets to which
this Agreement relates. “Affiliate” shall mean any entity that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with BUYER. Notwithstanding the above, SELLER shall have
the right to terminate this Agreement if the BUYER assigns this Agreement to a person or entity with which SELLER is prohibited by law from doing business. 

16. GOVERNING LAW; JURISDICTION OF DISPUTES 
 This
Agreement shall be governed by, subject to, and in accordance with the laws of the State of New York. Subject to Section 22.5, any dispute under or relating to this Agreement shall be commenced and resolved in a court of competent jurisdiction
located in the New York, using New York law. 
 17. TERMINATION OF AGREEMENT 

17.1 Termination without Cause 
 In addition to
all of its other termination rights hereunder, following the Initial Term of this Agreement, either party may terminate this Agreement, in whole or in part, together with any or all Statements of Work Pending Purchase Orders, without cause, upon
[***] notice to the other party. Upon any such termination, neither party shall have any further obligation or liability to the other party under this Agreement or any terminated Statements of Work Pending Purchase Orders, other than with respect to
work in progress and remittance of payment of the Purchase Price due hereunder for any Products accepted by BUYER hereunder prior to the effective date of termination. In order to allow Surplus Systems to be utilized during this period, SELLER shall
have no further obligation to maintain Surplus Systems as set forth in Section 10 following the issuance by either party of a notice of termination without cause. 

17.2 Termination for Default 
 A party shall
commit an “Event of Default” under this Agreement if: (i) such party fails in any material respect to perform or keep any of its obligations or covenants hereunder, or otherwise materially breaches this Agreement, and fails, in each
case, to cure such failure or breach within [***] after its receipt of written notice thereof from the other party; (ii) any representation or warranty made by such party herein is false or inaccurate in any material respect when made, or
becomes false or inaccurate in any material respect thereafter; or (iii) such party files a petition in 

  
 16 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
bankruptcy, or has filed against it an involuntary petition in bankruptcy not dismissed within [***] after filing, or applies for or consents to the appointment of a receiver, custodian, trustee
or liquidator, or makes a general assignment for the benefit of creditors. If a party commits an Event of Default (the “Defaulting Party”), then the other party (the “Non-Defaulting Party”) may terminate this Agreement upon
written notice to the Defaulting Party. Such termination shall be without prejudice to the Non-Defaulting Party’s other rights and remedies under this Agreement, at law, or in equity. 

17.3 Termination for Change of Control 
 In the
event of any change of control of SELLER that results in any of the companies identified in Attachment III having or gaining control over SELLER, BUYER shall be entitled to immediately terminate this Agreement upon providing written
notice to SELLER. For a period of [***] following the event the SELLER agrees to supply the BUYER, at BUYER’s discretion, with Products on terms no more or less onerous than those existing on the day before the change of control. SELLER shall
have no further obligation to maintain Surplus Systems as set forth in Section 10 following the issuance of written notice by BUYER to SELLER terminating this Agreement in accordance with this Section 17.3. 

17.4 Effect of Termination 
 In the event of a
termination or expiration of this Agreement, SELLER shall transmit to BUYER within [***] of such termination or expiration, any and all property, including, but not limited to, tooling, test fixtures, equipment, engineering diagrams, and blueprints,
that has been provided by BUYER, and all items listed on Attachment IV, all at the sole cost of BUYER. Should Purchase Orders remain in effect due to a Termination for Change of Control then within [***] of completion of such Purchase Orders, SELLER
shall return all such BUYER property to BUYER. Notwithstanding the above, SELLER shall be permitted to keep such information, tooling, test fixtures and equipment as may be necessary for SELLER to perform SELLER’S warranty obligations. 

Sections 14.1, 16, 17.4 and 20 shall survive any expiration or termination of this Agreement, and Sections 9, 12, 13, 14.2, 18, 21 and 22 shall survive any
expiration or termination of this Agreement, but only for a period of three (3) years. 
 18. ESCROW 

18.1 Within thirty (30) days after the Effective Date, SELLER shall deposit a copy of the Deposit Materials (as defined below) in a new
escrow account with Iron Mountain Intellectual Property Management, Inc. (“Escrow Agent”) pursuant to an escrow agreement substantially in the form of the escrow agreement attached hereto as (the “Escrow
Agreement”). The SELLER, BUYER and Escrow Agent shall execute the Escrow Agreement within thirty (30) days of the Effective Date. Pursuant to such Escrow Agreement, SELLER shall update the deposit [***] during the Term, or at major
design changes as requested by BUYER, to reflect changes in and additions to the Deposit Materials. Unless otherwise specified in the Escrow 

  
 17 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
Agreement, title to the Deposit Materials remains with SELLER. BUYER shall be entitled to audit the Deposit Materials at the time of deposit to ensure compliance with this Section 18.1,
provided that BUYER shall have no right to copy or retain the Deposit Materials until the occurrence of a Release Condition. SELLER shall provide to BUYER a notice [***] prior to a deposit or update of the Deposit Materials and BUYER shall have the
option of attending the audit. “Deposit Materials” means all drawings and manufacturing documents and other data and information relating to the Products that are at least sufficient to enable a reasonably skilled manufacturer in the trade
to manufacture Products, including the SELLER Know-How, and specifically part and assembly drawings, vendor specifications, and test and build travelers. SELLER shall be responsible for all out-of-pockets costs and expenses in establishing and
maintaining the Escrow Agreement. 
 18.2 Upon the occurrence of a Release Condition (as defined below and in the Escrow Agreement), for the
purpose of providing BUYER access to such technology as may be necessary or appropriate to permit it to manufacture or have manufactured Products, SELLER agrees that BUYER shall be entitled to delivery of a copy of the Deposit Materials, from the
Escrow Agent, and SELLER agrees to facilitate such delivery promptly following the occurrence of such Release Condition. Without overriding or modifying BUYER’s existing rights to all designs and manufacturing knowhow related to the System,
SELLER hereby further grants BUYER a non-exclusive right and license to use (and have used) the Deposit Materials after the occurrence of a Release Condition, solely to manufacture (or have manufactured) Products. SELLER agrees to provide reasonable
competent and knowledgeable assistance that is reasonably necessary for BUYER or its third party manufacturer to implement the Deposit Materials for the manufacture of Products. 

18.3 For the purpose this Agreement, a “Release Condition” shall mean any of the following events: (a) termination of the
Agreement by BUYER without cause pursuant to Section 17.1, (b) termination by BUYER for an Event of Default of SELLER pursuant to Section 17.2, (c) termination by BUYER due to a change of control of SELLER pursuant to
Section 17.3 or (d) termination of the Agreement by SELLER without cause pursuant to section 17.1. 
 18.4 In the event that
SELLER delivers the Deposit Materials in accordance with BUYER’s request following a Release Condition set forth in Section 18.3(a), BUYER shall, simultaneously with the receipt of such Deposit Materials, pay to SELLER [***]. In the event
that SELLER delivers the Deposit Materials in accordance with BUYER’s request following a Release Condition set forth in Sections 18.3(b) or (c), BUYER shall, simultaneously with the receipt of such Deposit Materials, pay to SELLER [***]. In
the event that SELLER delivers the Deposit Materials in accordance with BUYER’s request following a Release Condition set forth in Section 18.3 (d), BUYER shall, simultaneously with the receipt of such Deposit Materials, pay to SELLER
[***]. 

  
 18 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 19. FORCE MAJEURE 

Neither SELLER nor BUYER shall be considered in default or liable for failure to perform any provision of the Agreement if such delay or failure arises
directly or indirectly out of an act of nature, acts of the public enemy, unusually severe weather conditions, insurrection, riot, government actions (including delays caused by customs agencies other than for fault of SELLER) and other such causes
beyond the control of SELLER or BUYER, provided the affected party notifies the other party within [***] of occurrence. In the event the Force Majeure delay continues for a period of [***] or more, the other party may terminate this Agreement with
no further liability to the other party. 
 20. CONFIDENTIALITY; OWNERSHIP OF INTELLECTUAL PROPERTY 

20.1 The parties acknowledge and agree that all information or data disclosed by one party to the other shall be subject to the terms and
conditions of the Mutual Confidentiality Agreement attached hereto as Attachment VII. 
 20.2 Nothing in this Agreement shall affect the
ownership by either party of (a) any Intellectual Property or process owned by or in the possession of that party or its licensors at the date of this Agreement or (b) Intellectual Property developed independently of the work undertaken
under this Agreement by or on behalf of such party or its licensors without reference to any of the Confidential Information disclosed by the other party (“Independent Intellectual Property”). Other than giving SELLER the right to
manufacture the Products for BUYER, nothing in this Agreement shall give either Party the right to use the other Party’s Independent Intellectual Property. For purposes of this Agreement, “Intellectual Property” shall mean all
patents, patent applications, all provisional, divisional, continuations, renewals, continuations-in-part, re-examinations, patents of addition, supplementary protection certificates, extensions, letters of patent, registration or confirmation
patents and reissues with respect to any patents described in the foregoing clauses, any know-how, data, technology, copyrights, industrial property and technical information. 

20.3 It is agreed by the parties that (a) SELLER owns and shall own all Intellectual Property relating to the design and operation of
processing equipment and process implementation know how involved in their production of the [***] (“Jointly Owned Intellectual Property”). 

20.4 It is possible that, personnel of SELLER and BUYER will, independently or jointly, conceive of inventions or discoveries, relating to the
production, construction, or use of Jointly Owned Intellectual Property, or some aspect thereof. Except for improvements to SELLER’s or BUYER’S Intellectual Property, all such inventions concerning Jointly Owned Intellectual Property shall
be considered to be Jointly Owned Intellectual Property. In this respect, unless the Parties mutually agree to alternative responsibilities, decisions concerning applications for patent protection of any or all of these inventions shall be the
shared responsibility of SELLER and BUYER, who will provide notice to the other party of the invention and jointly file and prosecute such applications and maintain any resulting patents. 

  
 19 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
The Parties agree that each Party will promptly notify the other Party of when an invention concerning Jointly Owned Intellectual Property has been conceived. This discussion shall take place no
less frequently than once per quarter. When Jointly Owned Intellectual Property is developed during the Term of this Agreement, the Parties agree that, at any time they are free to engage in good faith discussion regarding the possibility that one
Party wishes to become sole owner of such property, and what consideration may be appropriate for such a change in ownership. 
 20.5 In the
event of the occurrence a Release Condition and receipt of the required payment to SELLER by BUYER, SELLER hereby grants to BUYER an irrevocable, perpetual, royalty-free, non-transferrable (except in accordance with Section 15), worldwide
license under Intellectual Property owned or controlled by SELLER solely to the extent necessary to manufacture or have manufactured Products for use in BUYER’s products, and for no other purpose. For the avoidance of doubt, the foregoing
license grant does not provide BUYER with any rights under SELLER’s Intellectual Property to manufacture any products other than Products, and does not permit BUYER to sublicense or otherwise transfer any such rights to any third party (other
than a third party that is manufacturing Products on a contract manufacture basis as BUYER’s agent for sale to BUYER.) The foregoing license does not provide BUYER with any rights to enforce any of SELLER’s Intellectual Property against
any third party or to prosecute or otherwise control SELLER’s maintenance of its Intellectual Property. 
 20.6 BUYER shall not be
restricted from note taking as long as the resulting records are maintained in accordance with the confidentiality provisions included in this Agreement. BUYER may have any picture taken of BUYER’s products in process by SELLER and provided to
BUYER in accordance with SELLER’s policy on use of cameras. 
 21. COMMUNICATION BETWEEN PARTIES 

All notices of default or termination required or permitted to be given under this Agreement shall be made in writing and shall be deemed to have been given
when personally delivered or when deposited for mailing by first class registered or certified mail, return receipt request, with proper postage prepaid and addressed as follows: 

 

							
		 	If to SELLER:	  	If to BUYER:	  	
				
		 	 Storrington Industries Limited
 Water Lane

Storrington, West Sussex, RH 20 3EA
 United Kingdom
	  	 Mevion Medical Systems, Inc.
 300 Foster
Street
 Littleton, MA 01460
 USA
	  	
				
		 	ATTN: Dr. Michael Begg	  	ATTN: Chief Executive Officer	  	
				
		 	 With a copy to:
 Plunkett & Graver,
PC.
 2030 Tilghman Street, Ste. 202
 Allentown, PA 18104

Attn: Joseph J. Plunkett, Esq.
	  	 With a copy to:
 Goodwin Procter LLP

53 State Street
 Boston, MA 02109

Attn.: Mitchell S. Bloom, Esq.
	  	

  
 20 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 22. GENERAL PROVISIONS 

22.1 Entire Agreement; Amendment 
 All Exhibits
and Attachments and schedules attached hereto as provided herein are all hereby incorporated as a part of this Agreement (collectively, the “Exhibits”). This Agreement, together with the Exhibits and any other documents specifically
incorporated by reference herein set forth the complete and final agreement and understanding of the parties relating to the subject matter hereof, and supersede and merge all prior and contemporaneous agreements, negotiations, and understandings
between the parties, both oral and written relating to the subject matter hereof. The terms of this Agreement shall supersede any terms and conditions in any acknowledgment form, invoice, or other document of Seller. Neither party has relied upon
any agreement, understanding, representation, warranty, or covenant not expressly set forth in writing herein. This Agreement may be amended only by a written instrument duly executed by both parties, and may not be amended orally or course of
performance. This Agreement may be executed in counterparts, each of which shall constitute an original, and all of which together shall constitute one and the same instrument. Signature pages may be delivered by PDF, facsimile or other electronic
means. Notwithstanding the foregoing, the provisions of the Existing Agreement shall continue to apply with respect to all rights and obligations of the Parties accruing prior to the Effective Date; and the provisions of the Existing Agreement will
be amended, superseded and replaced by this Agreement with respect to all rights and obligations of the parties with respect to any period(s) occurring or commencing, as of and after the Effective Date. 

22.2 Compliance with Laws 

(a) SELLER warrants that SELLER is in compliance with all applicable laws, rules and regulations governing international
transactions or activities including, but not limited to, export controls, import controls, customs regulations, trade embargoes and other trade sanctions and laws governing unlawful boycotts and payments to foreign government officials. 

(b) SELLER shall indemnify BUYER for any damages, penalties, fines, attorneys’ fees, or other losses of whatever kind or
nature resulting from, or arising out of, any violations by SELLER of any applicable laws, RULES or regulations governing international transactions or activities including, but not limited to, export controls, import controls, customs regulations,
trade embargoes and other trade sanctions, and laws governing unlawful boycotts and payments to foreign government officials. 

  
 21 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 22.3 Independent Contractor 

SELLER is an independent contractor of BUYER. Nothing shall be construed to create a partnership, joint venture or agency relationship between the parties.
Each party shall be solely responsible for payment of all compensation owed to its employees, as well as employment related taxes and benefits. Neither party has the right to create or assume any contractual or other obligation on behalf of the
other. 
 22.4 Waivers 
 All waivers hereunder
must be made in writing by a duly authorized representative of the party against whom the waiver is to operate, and failure at any time to require the other party’s performance of any obligation under this Agreement shall not affect the right
subsequently to require performance of that obligation. Each party’s rights and remedies hereunder shall be cumulative with, and may be exercised without prejudice to, such party’s other rights and remedies under this Agreement, at law, or
in equity. 
 22.5 Dispute Resolution 
 In the
event of a controversy, dispute or question arising out of or in connection with this Agreement, or the interpretation, performance or non-performance of this Agreement or any breach hereof, the parties agree that appropriate SELLER and BUYER
officers shall meet at a mutually agreeable time within [***] after such controversy, dispute or question is identified in order to attempt to resolve such controversy, dispute or question, before any other action may be brought by either party
hereunder. Any controversy, dispute or question arising out of or in connection with this Agreement, or the interpretation, performance or non-performance of this Agreement or any breach hereof, if not resolved to the satisfaction of both parties in
accordance with the preceding sentence within [***] of the date upon which both parties became aware of such controversy, dispute or question, shall be determined by arbitration pursuant to the then existing commercial arbitration rules of the
American Arbitration Association, in accordance with the following procedures. Arbitration shall be held in New York, New York, in the English language. The arbitration tribunal shall consist of three (3) arbitrators. Each party shall nominate,
in the request for arbitration and the answer thereto, one (1) arbitrator and the arbitrators so named shall then jointly appoint the third arbitrator to act as chairman of the arbitration tribunal. Any decision or award of such arbitration
tribunal shall be final, conclusive and binding on the parties hereto. Nothing contained in this Agreement shall in any way deprive either party of its right to obtain injunctions or other equitable relief from a court of competent jurisdiction,
including preliminary relief, pending arbitration. Any award rendered by an arbitrator shall be enforceable in any court of competent jurisdiction. 

22.6 Legal Costs and Expenses 
 If any suit or
legal proceeding is brought by either party to enforce any of the terms of this Agreement or any of its rights hereunder, the prevailing party in such action or proceeding shall be entitled to recover all of its reasonable costs and expenses
incurred in such suit or legal proceeding, including reasonable attorneys’ fees. 

  
 22 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 22.7 Severability 

In the event that any provision of the Agreement is determined by a court of competent jurisdiction to be illegal, invalid or otherwise unenforceable, under
applicable law, such provision shall be deemed severed from this Agreement, and all remaining provisions shall remain binding, enforceable, and in full force and effect. 

22.8 Counterparts, Fax and PDF 
 This Agreement
may be executed in several counterparts, which when taken together shall be deemed to be an original. Facsimile and/or PDF signatures shall be deemed to be original signatures. Each executed copy shall be deemed an original. 

[Remainder of page intentionally left blank. Signature page follows.] 

  
 23 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

							
	Accepted and Agreed to:	 		 	
			
	Mevion Medical Systems, Inc.	 		 	Storrington Industries Limited
			
	/s/ Joseph Jachinowski	 		 	/s/ Michael Begg
			
	 Name: Joseph Jachinowski
  

Title: CEO
	 		 	 Name: Michael Begg
  

Title: CEO

  
 24 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 EXHIBIT A-1 

STATEMENT OF WORK #1 
  

	1.	TITLE: Superconducting Magnet ( “System”) Build and Test. For purposes hereof, the System includes the cold mass, turret and cryostat assembly, supplied with
cryocooler heads installed. It does not include external cabling. Inclusion of the cryocompressors is at BUYER’s option. 

  

	2.	GENERAL: SELLER shall supply the system and certain components and manufacturing services to BUYER, specifically assembly and test of Systems (BUYER [***], SELLER [***], hereinafter referred to in this
Statement of Work as “Systems”) per BUYER specifications, and using SELLER manufacturing documents and processes. 

  

	3.	RELATIONSHIP TO AN UNDERLYING AGREEMENT: This SOW and the SPECIFIC TASKS described herein below are part of the Master Purchase Agreement entered into by and between SELLER and BUYER on
[            ] (the “Agreement”), and as such the terms and provisions of the Agreement also control over this Statement of Work. 

 

	4.	SPECIFIC TASKS and RESPONSIBILITIES: 

  

	 	a.	BUYER shall provide a quarterly forecast of production demand for Systems to SELLER. 

  

	 	b.	SELLER shall provide BUYER a quarterly forecast for [***] needs. 

  

	 	c.	BUYER shall manage procurement of materials for cold mass production, and provide sufficient conductor to enable SELLER to produce forecasted System demand. 

 

	 	d.	SELLER shall produce Systems at the rate and on the dates specified by BUYER. Lead time is [***]. For the purpose of delivery penalties (below), BUYER shall specifically firm forecast dates outside of this lead time.

  

	 	e.	SELLER shall perform final acceptance testing of the Systems, in complete accordance with BUYER specifications, [***]. The criteria set forth in this Section 4(e) are referred to as the “Acceptance
Criteria”) 

  

	 	f.	SELLER shall provide BUYER control over hold points in the System build, as determined by SELLER document 1113.QY. BUYER and SELLER jointly control the revision of 1113.QY. 1113.QY shall be defined so as to satisfy all
Acceptance Criteria. 

  

	 	g.	Upon completion of a successful test and review of data by BUYER, SELLER may ship each System to BUYER and invoice BUYER for each System in accordance with Section 6 below. 

 

	 	h.	All changes in design, process or test procedure shall be subject to Section 11 of the Agreement. 

  

	 	i.	SELLER to provide all parts with the exception of [***], which shall be provided by BUYER. 

  
 25 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

	 	j.	SELLER and BUYER acknowledge and agree that the failure of some limited number of specific temperature sensors shall not be deemed to be a failure to conform with the Acceptance Criteria set forth in any applicable
Statement of Work. This number and list of temperature sensors to be agreed to by both parties and reflected in changes to the specifications for the system. 

  
 26 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 EXHIBIT A-2 

FORM OF PURCHASE ORDER 
 [***] 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT I – 

PACKAGING INSTRUCTIONS 
 [***] 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT II – 

REQUIREMENTS FOR PACKING LIST AND INVOICE 
 [***]

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT III – 

CHANGE OF CONTROL 
 The parties agree that any
company producing or selling radiation therapy equipment, including, without limitation, the companies listed below and their affiliates and respective successors and assigns, would pose an unacceptable risk to BUYER’s business if they were to
gain control of SELLER. 
 [***] 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT IV 

Schedule of Mevion owned equipment 
 [***] 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT V 

Engineering Change Request (ECR) 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

					
	 Engineering Change Request             

  

	 	 	 
	EFACS Log No:	 	 	  	 
	 	 	 
	Drawing / Specification / Procedure No:	 	 	  	Issue:
	 		 
	Title:	 	 	  	 
	 	 
	Project:	 	Works Order:
			
	 DESCRIPTION OF CHANGE REQUIRED
  
	 		  	
	 	 	 
	 	 	 	  	 
			
	 REASON FOR CHANGE
  
	 		  	
	 	 	 
	 	 	 	  	 
			
	ORIGINATOR’S NAME / SIGNATURE:	 		  	DATE:
			
	 COMMENT BY DESIGN AUTHORITY
  
	 		  	
	 	 	 
	 	 	 	  	 
	 	 
	UL / TUV REPORT UPDATE    
 ̈    TICK IF APPLICABLE	  	APPLICABLE REPORT NO
	 	 
	RISK ASSESSMENT FOR MEDICAL PROCEDURES (REF 1014.QY)	  	         ̈ TICK IF APPLICABLE
	 	 
	ENVIROMENTAL ASPECTS (REF 1043.QY)	  	         ̈ TICK IF APPLICABLE
	 	 
	VERIFICATION AND VALIDATION OF CHANGE (REF 245.QY)	  	 
	 		 
	SIGNATURE	 	DATE	  	 
			
	CHANGE APPROVED / NOT APPROVED	 		  	DATE:
			
		 		  	QUALITY
			
		 		  	ENGINEERING
			
		 		  	PRODUCTION
		
	COSTS AGREED (CUSTOMER) AND APPROVED	  	DATE:
			
		 		  	CUSTOMER

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT VI 

Form of Escrow Agreement 
 [***] 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ATTACHMENT VII 

MUTUAL CONFIDENTIALITY AGREEMENT 

This Agreement is made by and between Mevion Medical System, Inc., a Delaware corporation (the “Buyer”), having a
principal place of business at 300 Foster Street Littleton, Massachusetts 01460, USA and Storrington Industries, Limited (the “Supplier”), having a principal place of business at Water Lane, Storrington, West Sussex, RH20 3EA,
UK. 
 1. Definition of Confidential Information. “Confidential Information” as used in this Agreement shall
mean any and all technical and non-technical information including, without limitation, patent, copyright, trade secret and proprietary information, techniques, sketches, drawings, models, inventions, know-how, processes, formulae, apparatus,
equipment and biological materials related to the current, future and proposed products and services of each of the parties, and includes, without limitation, their respective information concerning research, experimental work, development, design
details and specifications, engineering, financial information, procurement requirements, purchasing, manufacturing, customer lists, business forecasts and sales and marketing plans “Confidential Information” also includes
proprietary or confidential information of any third party who may disclose such information to either party in the course of the other party’s business. Such information disclosed by the disclosing party (“Discloser”) will be
considered Confidential Information by the receiving party (“Recipient”), only if such information is conspicuously designated as “Confidential”, or if provided orally, identified as confidential at the time of disclosure
and confirmed in writing within thirty (30) days of disclosure. 
 2. Nondisclosure and Nonuse Obligation. Each of the parties
agrees that it will not make use of, disseminate, or in any way disclose any Confidential Information of the other party to any person, firm or business, except to the extent necessary for negotiations, discussions, and consultations with personnel
or authorized representatives of the other party, and any purpose the other party may hereafter authorize in writing. Furthermore, the existence of any business negotiations, discussions, consultations or agreements in progress between the parties
shall not be released to any form of public media without written approval of both parties. Each of the parties agrees that it shall treat all Confidential Information of the other party with the same degree of care as it accords to its own
Confidential Information, and each of the parties represents that it exercises reasonable care to protect its own Confidential Information. If either party is not an individual, such party agrees that it shall disclose Confidential Information of
the other party only to those of its employees who need to know such information and certifies that such employees have previously agreed, either as a condition to employment or in order to obtain the Confidential Information, to be bound by terms
and conditions substantially similar to those of this Agreement. Recipient will immediately give notice to Discloser of any unauthorized use or disclosure of the Confidential Information. Recipient agrees to assist Discloser in remedying any such
unauthorized use or disclosure of the Confidential Information. Except as required by law, neither party shall use the name of the other party or reveal the existence or substance of ongoing discussions, negotiations, or evaluations related to the
subject matter of this Agreement, or any subsequently executed agreement, to any third party without the prior written consent of the other party, which consent shall not be unreasonably withheld. 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 3. Exclusions from Nondisclosure and Nonuse Obligations. Each party’s obligations
under Paragraph 2 (“Nondisclosure and Nonuse Obligations”) with respect to any portion of the other party’s Confidential Information shall terminate when the party seeking to avoid its obligation under such Paragraph can
document that: (i) it was in the public domain at or subsequent to the time it was communicated to Recipient by Discloser through no fault of Recipient; (ii) it was rightfully in Recipient’s possession free of any obligation of
confidence at or subsequent to the time it was communicated to Recipient by Discloser; (iii) it was developed by employees or agents of Recipient independently of and without reference to any information communicated to Recipient by Discloser;
(iv) it was communicated by the Discloser to an unaffiliated third party free of any obligation of confidence; or (v) the communication was in response to a valid order by a court or other governmental body, was otherwise required by law,
or was necessary to establish the rights of either party under this Agreement. 
 4. Ownership of Confidential Information and Other
Materials. All Confidential Information, and any Derivatives thereof whether created by Discloser or Recipient, remain the property of Discloser and no license or other rights to Confidential Information is granted or implied hereby. For
purposes of this Agreement, “Derivatives” shall mean: (i) for copyrightable or copyrighted material, any translation, abridgement, revision or other form in which an existing work may be recast, transformed or adapted;
(ii) for patentable or patented material, any improvement thereon; and (iii) for material which is protected by trade secret, any new material derived from such existing trade secret material, including new material which may be protected
by copyright, patent and/or trade secret. All materials (including without limitation, documents, drawings, models, apparatus, sketches, designs and lists) furnished to one party by the other, and which are designated in writing to be the property
of such party, shall remain the property of such party and shall be returned to it promptly at its request, together with any copies thereof. 

5. Independent Development. Discloser understands that Recipient may currently or in the future be developing information internally,
or receiving information from other parties that may be similar to Discloser’s information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Recipient will not develop products, or have products
developed for it, that, without violation of this Agreement, compete with the products or systems contemplated by Discloser’s Confidential Information. 

6. Disclosure of Third Party Information. Neither party shall communicate any information to the other in violation of the proprietary
rights of any third party. 
 7. No Warranty. All Confidential Information is provided “AS IS” and without any warranty,
express, implied or otherwise, regarding its accuracy or performance. 
 8. No Export. Neither party shall export, directly or
indirectly, any technical data acquired from the other pursuant to this Agreement or any product utilizing any such data to any country for which the U.S. Government or any agency thereof at the time of export requires an export license or other
government approval without first obtaining such license or approval. 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 9. Term. This Agreement shall govern all communications between the parties that are
made during the period from the effective date of this Agreement to the date on which either party receives from the other written notice that subsequent communications shall not be so governed; provided, however, that each
party’s Nondisclosure and Nonuse Obligations with respect to Confidential Information of the other party which it has previously received shall continue in perpetuity unless terminated pursuant to Paragraph 3 (“Exclusions from
Nondisclosure and Nonuse Obligations”). 
 10. Notices. Any notice required or permitted by this Agreement shall be in
writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by telecopy or facsimile
transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth above or such other address
as either party may specify in writing. 
 11. Governing Law. This Agreement shall be governed in all respects by the laws of the
United States of America and by the laws of the State of New York, as such laws are applied to agreements entered into and to be performed entirely within New York between New York residents. 

12. Severability. Should any provisions of this Agreement be held by a court of law to be illegal, invalid or unenforceable, the
legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby. 
 13.
Waiver. The waiver by Discloser of a breach of any provision of this Agreement by Recipient shall not operate or be construed as a waiver of any other or subsequent breach by Recipient. 

14. Injunctive Relief. A breach of any of the promises or agreements contained herein will result in irreparable and continuing damage
to the non-breaching party for which there will be no adequate remedy at law, and the non-breaching party shall be entitled to injunctive relief and/or a decree for specific performance, and such other relief as may be proper (including monetary
damages if appropriate). 
 15. Entire Agreement. This Agreement constitutes the entire agreement with respect to the Confidential
Information disclosed herein and supersedes all prior or contemporaneous oral or written agreements concerning such Confidential Information. This Agreement may only be changed by mutual agreement of authorized representatives of the parties in
writing. 

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

 

									
	 	 	 MEVION MEDICAL SYSTEMS, INC.

 
	 	 	 	 	 	 STORRINGTON
INDUSTRIES LIMITED
  

	 		 		 
	 	 	Signature	 	 	 		 	Signature
	 		 		 
	 	 	  
	 	 	 		 	  

	 		 		 
	 	 	Name:	 	 	 		 	Name:
	 		 		 
	 	 	  
	 	 	 		 	  

	 		 		 
	 	 	Title:	 	 	 		 	Title:EX-10.2

 Exhibit 10.2 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

MASSACHUSETTS INSTITUTE OF TECHNOLOGY 

and 
 STILL RIVER SYSTEMS,
INC. 
 PATENT LICENSE AGREEMENT 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 TABLE OF CONTENTS 
  

			
	 TABLE OF CONTENTS
	  	ii
	 R E C I T A L S
	  	1
	 1. Definitions
	  	2
	 2. Grant of Rights
	  	5
	 3. Company Exclusivity and Diligence Obligations
	  	8
	 4. Royalties and Payment Terms
	  	9
	 5. Reports and Records
	  	11
	 6. Patent Prosecution
	  	13
	 7. Infringement
	  	14
	 8. Indemnification and Insurance
	  	16
	 9. No Representations or Warranties
	  	17
	 10. Assignment
	  	18
	 11. General Compliance with Laws
	  	18
	 12. Termination
	  	19
	 13. Dispute Resolution
	  	21
	 14. Miscellaneous
	  	23
	 APPENDIX A
	  	27
	 APPENDIX B
	  	28

  
 ii 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 MASSACHUSETTS INSTITUTE OF TECHNOLOGY 

EXCLUSIVE PATENT LICENSE AGREEMENT 

This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the
Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Still River Systems, Inc. (“COMPANY”), a Delaware corporation, with a
principal place of business at 300 Foster Street, Littleton, MA 01460. 
 R E C I T A L S 

WHEREAS, M.I.T. and COMPANY are parties to that certain Sponsored Research Agreement dated July 1, 2004 pursuant to which M.I.T. granted
COMPANY the right to take a license to certain inventions conceived by M.I.T. during the performance of the sponsored research; 
 WHEREAS,
M.I.T. and COMPANY entered into a Patent License Agreement dated August 17, 2006 (the “2006 PATENT LICENSE”); 
 WHEREAS,
M.I.T. is the owner of certain PATENT RIGHTS (as later defined herein) relating to [***]; 
 WHEREAS, M.I.T. desires to have the PATENT
RIGHTS developed and commercialized to benefit the public and is willing to grant a license thereunder; and 
 WHEREAS, COMPANY and M.I.T.
desire to establish a new license to replace the 2006 PATENT LICENSE upon the terms and conditions hereinafter set forth. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 NOW, THEREFORE, M.I.T. and COMPANY hereby agree as follows: 

1. DEFINITIONS. 
 1.1
“AFFILIATE” shall mean any legal entity (including, but not limited to, a corporation, partnership, or limited liability company) that is controlled by COMPANY. For the purposes of this definition, the term “control” means
(i) beneficial ownership of at least fifty percent (50%) of the voting securities of a corporation or other business organization with voting securities or (ii) a fifty percent (50%) or greater interest in the net assets or
profits of a partnership or other business organization without voting securities. 
 1.2 “CLINICAL INSTALLATION” shall mean a
PROTON CYCLOTRON that is a LICENSED PRODUCT shipped to a customer site as agreed between COMPANY and its customer. 
 1.3 “COMMERCIAL
SALE” shall mean the event when COMPANY can first recognize revenue for the sale of a LICENSED PRODUCT according to Generally Accepted Accounting Practices (GAAP) in the United States of America. 

1.4 “FIELDS OF USE” shall mean the fields defined below: 

(a) “EXCLUSIVE FIELD ONE” shall mean [***].

(b) “EXCLUSIVE FIELD TWO” shall mean [***]. 

(c) “NON-EXCLUSIVE FIELD” shall mean proton radiotherapy medical installations. 

1.5 “LICENSED PRODUCT” shall mean any product the manufacture, use, sale or importation of which, absent the license granted
hereunder, would infringe one or more VALID CLAIMS within the PATENT RIGHTS. The parties acknowledge and agree that the PROTON CYCLOTRON and/or components thereof which COMPANY plans to commercialize as part of its Monarch 250 TM Treatment
System (including as it exists as of the EFFECTIVE DATE) is the initial LICENSED PRODUCT developed hereunder. 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 1.6 “NET SALES” shall mean the gross amount received by COMPANY and its
AFFILIATES and SUBLICENSEES for LICENSED PRODUCTS including any pre-payments for LICENSED PRODUCTS, less the following: 
 (i) customary
trade, quantity, or cash discounts to the extent actually allowed and taken; 
 (ii) amounts repaid or credited by reason of rejection or
return; 
 (iii) to the extent separately stated on purchase orders, invoices, or other documents of sale, any taxes or other governmental
charges levied on the production, sale, transportation, delivery, or use of a LICENSED PRODUCT which is paid by or on behalf of COMPANY; and 

(iv) outbound transportation costs prepaid or allowed and costs of insurance in transit. 

No deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed by
COMPANY and on its payroll, or for cost of collections. If a LICENSED PRODUCT is distributed at a discounted price that is substantially lower than the customary price charged by COMPANY, or distributed for non-cash consideration (whether or not at
a discount), NET SALES shall be calculated based on the non-discounted amount charged to an independent third party for LICENSED PRODUCT sold during the same REPORTING PERIOD or, in the absence of such sales, on the fair market value of the LICENSED
PRODUCT. 
 1.7 “PATENT CHALLENGE” shall mean a challenge to the validity, patentability, and/or enforceability of any of
the PATENT RIGHTS (as defined below) or otherwise opposing any of the PATENT RIGHTS. It is understood and agreed that good faith efforts to confirm and/or correct inventorship on any patent, as defined in Section 1.8 (b), (c), (d), or
(e) below, granted after the EFFECTIVE DATE shall not be deemed a PATENT CHALLENGE. The foregoing notwithstanding, COMPANY, based on its reasonable review of the PATENT RIGHTS documents published before the EFFECTIVE DATE and cited in
Section 1.8, knows of no reason that confirmation and/or correction of inventorship on any patent defined in Section 1.8 (b), (c), (d), or (e) is warranted. 

  
 3 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 1.8 “PATENT RIGHTS” shall mean: 

(a) the United States and international patents listed on Appendix A; 

(b) the United States and international patent applications and/or provisional applications listed on Appendix A and the patents
issuing therefrom; 
 (c) any patent applications claiming priority to or converted from the provisional applications listed on Appendix
A, and any divisionals, continuations, continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed on Appendix A and of such patent
applications claiming priority to or converted from the provisional applications listed on Appendix A, to the extent the claims are directed to subject matter specifically described in the patent applications listed on Appendix A, and
the patents issuing therefrom; 
 (d) any patents issuing from reissues, reexaminations, or extensions (and their relevant international
equivalents) of the patents described in (a), (b), and (c) above; and 
 (e) international (non-United States) patent applications and
provisional applications filed after the EFFECTIVE DATE and claiming priority to any of the applications listed on Exhibit A or converted from any provisional applications listed on Appendix A and the relevant international equivalents to
divisionals, continuations, continuation-in-part applications and continued prosecution applications of those patent applications to the extent the claims are directed to subject matter specifically described in the patents or patent applications
referred to in (a), (b), (c), and (d) above, and the patents issuing therefrom. 
 1.9 “311 PATENT” shall mean [***]. 

1.10 “PROTON CYCLOTRON” shall mean a device composed of a magnet, cryogenic cooler, ion source, beam extraction and focusing
system, accelerating dees, the charging and protection system for the magnet, cryogenic cooler, RF power supply and its instrumentation and control, and vacuum equipment. It does not include the gantry, inner gantry, treatment room environment,
couch, non-PROTON CYCLOTRON control system, software, installation, and training. 
 1.11 “REPORTING PERIOD” shall begin on
the first day of each calendar quarter and end on the last day of such calendar quarter. 

  
 4 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 1.12 “SUBLICENSE INCOME” shall mean any payments that COMPANY or an
AFFILIATE receives from a SUBLICENSEE in consideration of the sublicense of the rights granted COMPANY and AFFILIATES under Section 2.1, including without limitation license fees, milestone payments, license maintenance fees, and other
payments, but specifically excluding royalties based on sales of LICENSED PRODUCT by such SUBLICENSEE. Amounts paid to COMPANY or an AFFILIATE by a SUBLICENSEE as an equity investment, or to sponsor research, or in consideration for goods and
services provided by COMPANY shall not be SUBLICENSE INCOME. 
 1.13 “SUBLICENSEE” shall mean any non-AFFILIATE sublicensee
of the rights granted COMPANY under Section 2.1. 
 1.14 “TERM” shall mean the term of this Agreement, which shall
commence on the EFFECTIVE DATE and shall remain in effect until the expiration or termination of the last VALID CLAIM within the PATENT RIGHTS, unless earlier terminated in accordance with the provisions of this Agreement. 

1.15 “TERRITORY” shall mean world-wide. 

1.16 “TREATMENT GANTRY” shall mean an apparatus that directs a proton beam to a patient treatment isocenter [***]. 

1.17 “VALID CLAIM” shall mean (i) a pending claim in any patent application within the PATENT RIGHTS that has not been
pending for more than six (6) years, or (ii) a claim of any issued patent within the PATENT RIGHTS that has not been held unenforceable or invalid by a final decision of a court or other government agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

2. GRANT OF RIGHTS. 
 2.1
License Grants. Subject to the terms of this Agreement, M.I.T. hereby grants to COMPANY and its AFFILIATES for the TERM a royalty-bearing license under the PATENT RIGHTS to develop, make, have made, use, sell, offer to sell, lease, and import
LICENSED PRODUCTS in the FIELDS OF USE in the TERRITORY. 

  
 5 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 2.2 Exclusivity. Except as cited in Section 2.5 below, M.I.T. has not granted any
license under the PATENT RIGHTS in EXCLUSIVE FIELD ONE or in EXCLUSIVE FIELD TWO, and M.I.T. agrees that it shall not grant any other license in the TERRITORY to offer to sell, sell, lease, or import LICENSED PRODUCTS in EXCLUSIVE FIELD ONE during
the term of EXCLUSIVE FIELD ONE as defined in Section 3.1 below and/or to, develop, make, have made, use, sell, offer to sell, lease, or import LICENSED PRODUCTS in EXCLUSIVE FIELD TWO during the terms of EXCLUSIVE FIELD ONE and EXCLUSIVE FIELD
TWO as respectively defined in Sections 3.1 and 3.2 below. 
 2.3 Sublicenses. COMPANY shall have the right to grant sublicenses of
its rights under Section 2.1, but only in EXCLUSIVE FIELD TWO during the terms of EXCLUSIVE FIELD ONE and EXCLUSIVE FIELD TWO as respectively defined in Sections 3.1 and 3.2 below. COMPANY shall incorporate terms and conditions into its
sublicense agreements sufficient to enable COMPANY to comply with this Agreement. COMPANY shall promptly furnish M.I.T. with a fully signed photocopy of any sublicense agreement. Upon termination of this Agreement for any reason, any SUBLICENSEE not
then in default shall have the right to seek a license from M.I.T. M.I.T. agrees to negotiate such licenses in good faith under reasonable terms and conditions. 

COMPANY shall have the right to grant sublicenses of its rights under Section 2.1 outside of EXCLUSIVE FIELD TWO with the consent of
M.I.T. which consent shall not be unreasonably withheld. 
 2.4 U.S. Manufacturing. COMPANY agrees that any LICENSED PRODUCTS used or
sold in the United States will be manufactured substantially in the United States as and to the extent required by applicable law. 

  
 6 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 2.5 Retained Rights. 

(a) Research and Educational Use. M.I.T. retains the right on behalf of itself and all other non-profit research institutions to
practice under (i) the PATENT RIGHTS and (ii) 311 PATENT in the event [***]. 
 (b) Federal Government. COMPANY
acknowledges that the U.S. federal government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded invention claimed in any PATENT RIGHTS as set forth in 35 U.S.C. §§ 201-211, and the
regulations promulgated thereunder, as amended, or any successor statutes or regulations. 
 2.6 License Grants in [***]. 

(a) Grant from COMPANY to M.I.T. COMPANY hereby grants to M.I.T. a perpetual, worldwide, royalty-free license with the right to
sublicense under 311 PATENT to develop, make, have made, use, sell, offer to sell, lease, or import products in all fields except M.I.T. shall not have the rights (i) to sublicense the right to sell, offer to sell, lease, or import products in
EXCLUSIVE FIELD ONE during the term of EXCLUSIVE FIELD ONE as defined in Section 3.1 below or (ii) to sublicense the right to develop, make, have made, use, sell, offer to sell, lease, or import products in EXCLUSIVE FIELD TWO. 

(b) Grant from M.I.T. to COMPANY. In the event M.I.T. becomes a co-owner of [***] or any other patent or patent application coming
within the definition of 311 PATENT in Section 1.9 above, M.I.T. agrees that it shall not grant any license under [***] or any other patent or patent application coming within the definition of 311 PATENT in Section 1.9 above (i) to
offer to sell, sell, lease, or import products in EXCLUSIVE FIELD ONE during the term of EXCLUSIVE FIELD ONE as defined in Section 3.1 below or (ii) to develop, make, have made, use, sell, offer to sell, lease, or import products in
EXCLUSIVE FIELD TWO. 
 (c) Rights in EXCLUSIVE FIELD TWO. M.I.T. shall have no right to grant rights under [***] or any other patent
or patent application coming within the definition of 311 PATENT in Section 1.9 above in EXCLUSIVE FIELD TWO. 

  
 7 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 2.7 No Additional Rights. Nothing in this Agreement shall be construed to confer any
rights upon COMPANY by implication, estoppel, or otherwise as to any technology or patent rights of M.I.T. or any other entity other than the PATENT RIGHTS, regardless of whether such technology or patent rights shall be dominant or subordinate to
any PATENT RIGHTS. 
 3. COMPANY EXCLUSIVITY AND DILIGENCE OBLIGATIONS. 

3.1 The term of exclusivity for EXCLUSIVE FIELD ONE shall begin on EFFECTIVE DATE and continue until December 31, 2014 provided that
COMPANY shall have achieved at least three (3) CLINICAL INSTALLATIONS by December 31, 2013. If COMPANY shall have achieved at least seven (7) CLINICAL INSTALLATIONS by June 30, 2014, the term of EXCLUSIVE FIELD ONE shall continue
until June 30, 2015. If COMPANY has not achieved three (3) CLINICAL INSTALLATIONS by December 31, 2013, COMPANY’s exclusivity for EXCLUSIVE FIELD ONE shall end on December 31, 2013. If COMPANY has achieved at least three
(3) CLINICAL INSTALLATIONS by December 31, 2013 and COMPANY has not achieved at least seven (7) CLINICAL INSTALLATIONS by June 30, 2014, COMPANY’s exclusivity for EXCLUSIVE FIELD ONE shall end on December 31, 2014. 

3.2 The term of exclusivity for EXCLUSIVE FIELD TWO shall begin at the end of the term of exclusivity for EXCLUSIVE FIELD ONE and continue for
the TERM, provided however, if COMPANY has not achieved at least four (4) new CLINICAL INSTALLATIONS in the first full calendar year of the term of exclusivity for EXCLUSIVE FIELD TWO and each subsequent year thereafter, then all exclusivity
shall end and the COMPANY shall thereafter have only a non-exclusive license in the NON-EXCLUSIVE FIELD. 

  
 8 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 4. ROYALTIES AND PAYMENT TERMS. 

4.1 Consideration for Grant of Rights. 

(a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to M.I.T. on the EFFECTIVE DATE a license issue fee of Three
Hundred Thousand dollars ($300,000), and, in accordance with Section 6.3, shall reimburse M.I.T. for its actual expenses incurred, not to exceed [***] as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are
nonrefundable. 
 (b) License Maintenance Fees. COMPANY shall pay to M.I.T. the following license maintenance fees on the dates set
forth below: 
  

					
	 January 1, 2012
	  	$	[	***] 
	 January 1, 2013
	  	$	[	***] 
	 January 1, 2014
	  	$	[	***] 
	 and each January 1 of every year thereafter
	  	$	[	***] 

 This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to
running royalties subsequently due pursuant to Section 4.1 (c) during the same calendar year, if any. License maintenance fees paid in excess of running royalties due in such calendar year shall not be creditable to amounts due for future
years. 
 (c) Running Royalties. COMPANY shall pay to M.I.T. a running royalty of [***] of NET SALES, but in no event [***]
(hereinafter a “MINIMUM ROYALTY”) or [***] for each COMMERCIAL SALE of a LICENSED PRODUCT by COMPANY, AFFILIATES and SUBLICENSEES during the REPORTING PERIOD. [***] In the event that a LICENSED PRODUCT is shipped to a customer site by
COMPANY, an AFFILIATE, or a SUBLICENSEE without a COMMERCIAL SALE within [***] of said shipment, then COMPANY shall pay to M.I.T. a running royalty based on the market value of the LICENSED PRODUCT determined by the amount charged to an independent
third party for LICENSED PRODUCT sold during the same REPORTING PERIOD. Running royalties shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within [***] of the end of each REPORTING PERIOD. 

  
 9 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 (d) Sharing of SUBLICENSE INCOME. COMPANY shall pay M.I.T. a total of [***] of all
SUBLICENSE INCOME received by COMPANY or AFFILIATES. Such amount shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within [***] of the end of each REPORTING PERIOD. 

(f) Milestone payment for FDA approval. [***] shall be due to M.I.T. upon receipt of FDA approval for marketing of a LICENSED PRODUCT.

 (e) Consequences of a PATENT CHALLENGE. In the event that (i) COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE
against M.I.T., or (ii) COMPANY or any of its AFFILIATES assists another party in bringing a PATENT CHALLENGE against M.I.T. (except as required under a court order or subpoena), and (iii) M.I.T. does not choose to exercise its rights to
terminate this Agreement pursuant to Section 12.4, then the running royalties due hereunder shall be doubled for the remainder of the term of the AGREEMENT. In the event that such a PATENT CHALLENGE is successful, COMPANY will have no right to
recoup any royalties paid during the period of challenge. In the event that a PATENT CHALLENGE is unsuccessful, COMPANY shall reimburse M.I.T. for all reasonable legal fees and expenses incurred in its defense against the PATENT CHALLENGE. 

(g) No Multiple Royalties. If the manufacture, use, lease, or sale of any LICENSED PRODUCT is covered by more than one of the PATENT
RIGHTS, multiple royalties shall not be due. 
 4.2 Payments. 

(a) Method of Payment. All payments under this Agreement should be made payable to “Massachusetts Institute of Technology”
and sent to the address identified in Section 14.1. Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies. 

  
 10 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 (b) Payments in U.S. Dollars. All payments due under this Agreement shall be drawn on
a United States bank and shall be payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported by the Federal Reserve Bank of St. Louis) on the last
working day of the calendar quarter of the applicable REPORTING PERIOD. Such payments shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government
imposed fees or taxes, except as permitted in the definition of NET SALES. 
 (c) Late Payments. Any payments by COMPANY that are not
paid on or before the date such payments are due under this Agreement shall bear interest, to the extent permitted by law, at two percentage points above the Prime Rate of interest as reported by the Federal Reserve Bank of St. Louis on the date
payment is due. 
 5. REPORTS AND RECORDS. 

5.1 Frequency of Reports. 

(a) Before First COMMERCIAL SALE. Prior to the date of the first COMMERCIAL SALE of any LICENSED PRODUCT, COMPANY shall deliver reports
to M.I.T. annually, within [***] of the end of each calendar year, containing information concerning the immediately preceding calendar year, as further described in Section 5.2. 

(b) Upon First COMMERCIAL SALE of a LICENSED PRODUCT. COMPANY shall report to M.I.T. the date of first COMMERCIAL SALE of a LICENSED
PRODUCT within [***] of occurrence in each country. 
 (c) After First COMMERCIAL SALE. After the first COMMERCIAL SALE of a LICENSED
PRODUCT, COMPANY shall deliver reports to M.I.T. within [***] of the end of each REPORTING PERIOD, containing information concerning the immediately preceding REPORTING PERIOD, as further described in Section 5.2. 

  
 11 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 5.2 Content of Reports and Payments. Each report delivered by COMPANY to M.I.T. shall
contain at least the following information for the immediately preceding REPORTING PERIOD: 
 (i) the number of LICENSED PRODUCTS sold,
leased or distributed by COMPANY, its AFFILIATES and SUBLICENSEES to independent third parties in each country, and, if applicable, the number of LICENSED PRODUCTS used by COMPANY, its AFFILIATES and SUBLICENSEES in the provision of services in each
country; 
 (ii) total royalty payable pursuant to Section 4.1(c); 

(iii) the amount of SUBLICENSE INCOME received by COMPANY from each SUBLICENSEE and the amount due to M.I.T. from such SUBLICENSE INCOME,
including an itemized breakdown of the sources of income comprising the SUBLICENSE INCOME; and 
 (iv) the number of sublicenses entered
into for the PATENT RIGHTS, LICENSED PRODUCTS. 
 If no amounts are due to M.I.T. for any REPORTING PERIOD, the report shall so state. 

5.3 Financial Statements. On or before the ninetieth (90th) day following the close of COMPANY’s fiscal year, COMPANY shall
provide M.I.T. with a copy of COMPANY’s financial statements for the preceding fiscal year including, at a minimum, a balance sheet and an income statement, certified by COMPANY’s treasurer or chief financial officer or by an independent
auditor. 
 5.4 Records. COMPANY shall maintain, and shall cause its AFFILIATES and SUBLICENSEES to maintain, complete and accurate
records relating to the rights and obligations under this Agreement and any amounts payable to M.I.T. in relation to this Agreement, which records shall contain sufficient information to permit M.I.T. to confirm the accuracy of any reports delivered
to M.I.T. and compliance in other respects with this Agreement. The relevant party shall retain such records for at least [***] following the end of the calendar year to which they pertain, during which time M.I.T., or M.I.T.‘s appointed
agents, 

  
 12 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
shall have the right, at M.I.T.‘s expense, to inspect such records during normal business hours to verify any reports and payments made or compliance in other respects under this Agreement.
In the event that any audit performed under this Section reveals an underpayment [***] COMPANY shall bear the full cost of such audit and shall remit any amounts due to M.I.T. within [***] of receiving notice thereof from M.I.T. 

6. PATENT PROSECUTION. 

6.1 Responsibility for PATENT RIGHTS. M.I.T. shall prepare, file, prosecute, and maintain all of the PATENT RIGHTS using attorneys
reasonable acceptable to COMPANY, such acceptance not to be unreasonably withheld or delayed. COMPANY shall have reasonable opportunity to review and comment on all filings with all patent offices, and M.I.T. shall take comments provided by COMPANY
into good faith consideration. COMPANY shall cooperate with M.I.T. in such filing, prosecution and maintenance. 
 If M.I.T. decides to
abandon any PATENT RIGHTS it shall give reasonable notice to COMPANY and COMPANY shall have the right to be able to continue the prosecution and maintenance of any such PATENT RIGHTS and COMPANY shall not be subject to any payments or royalties
under this Agreement for sales of any LICENSED PRODUCT covered by any claim of such PATENT RIGHTS. 
 6.2 International (non-United
States) Filings. Appendix B is a list of countries in which patent applications corresponding to the United States patent applications listed in Appendix A shall be filed, prosecuted, and maintained. Appendix B may be
amended by mutual agreement of COMPANY and M.I.T. 
 6.3 Payment of Expenses. Payment of all fees and costs, including attorneys
fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS shall be the responsibility of COMPANY, whether such amounts were incurred before or after the EFFECTIVE DATE. [***] COMPANY shall reimburse all amounts due pursuant to
this Section within [***] of invoicing; late payments shall accrue interest pursuant to Section 4.2(c). In all instances, M.I.T. shall pay the fees prescribed for large entities to the United States Patent and Trademark Office. 

  
 13 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 If M.I.T. licenses any of the PATENT RIGHTS to another commercial entity, M.I.T. shall
require that entity to share the burden of future patent expenses with COMPANY on a pro rata basis. 
 7. INFRINGEMENT. 

7.1 Notification of Infringement. Each party agrees to provide written notice to the other party promptly after becoming aware of any
infringement of the PATENT RIGHTS. 
 7.2 Right to Prosecute Infringements. 

(a) COMPANY Right to Prosecute. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the EXCLUSIVE FIELD ONE or
EXCLUSIVE FIELD TWO in the TERRITORY, COMPANY, to the extent permitted by law, shall have the right, under its own control and at its own expense, to prosecute any third party infringement of the PATENT RIGHTS in the respective EXCLUSIVE FIELD ONE
or EXCLUSIVE FIELD TWO in the TERRITORY, subject to Sections 7.4 and 7.5. If required by law, M.I.T. shall permit any action under this Section to be brought in its name, including being joined as a party-plaintiff, provided that COMPANY shall
hold M.I.T. harmless from, and indemnify M.I.T. against, any costs, expenses, or liability that M.I.T. incurs in connection with such action. 

Prior to commencing any such action, COMPANY shall consult with M.I.T. and shall consider the views of M.I.T. regarding the advisability of
the proposed action and its effect on the public interest. COMPANY shall not enter into any settlement, consent judgment, or other voluntary final disposition of any infringement action under this Section without the prior written consent of M.I.T.
which shall not be unreasonably withheld and which shall take into full consideration the business implications to COMPANY. 
 (b) M.I.T.
Right to Prosecute. In the event that COMPANY is unsuccessful in persuading the alleged infringer to desist or fails to have initiated an infringement action within a reasonable time after COMPANY first becomes aware of the basis for such
action, M.I.T. shall have the right, at its sole discretion, to prosecute such infringement under its sole control and at its sole expense, and any recovery obtained shall belong to M.I.T. 

  
 14 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 7.3 Declaratory Judgment Actions. In the event that a PATENT CHALLENGE is brought
against M.I.T. or COMPANY by a third party, M.I.T., at its option, shall have the right within twenty (20) days after commencement of such action to take over the sole defense of the action at its own expense. If M.I.T. does not exercise this
right, COMPANY may take over the sole defense of the action at COMPANY’s sole expense, subject to Sections 7.4 and 7.5. 
 7.4
Offsets. COMPANY may offset a total of fifty percent (50%) of any expenses incurred under Sections 7.2 and 7.3 against any payments due to M.I.T. under Sections 4.1(b) and 4.1(c), provided that in no event shall such payments under
Sections 4.1(b) and 4.1(c), when aggregated with any other offsets and credits allowed under this Agreement, be reduced by more than fifty percent (50%) in any REPORTING PERIOD. 

7.5 Recovery. Any recovery settlement obtained in an action brought by COMPANY under Sections 7.2 or 7.3 shall be distributed as
follows: (i) each party shall be reimbursed for any expenses incurred in the action (including the amount of any royalty or other payments withheld from M.I.T. as described in Section 7.4 and any costs paid by COMPANY on behalf of M.I.T.
under Section 7.2(a), (ii) as to ordinary damages, COMPANY shall receive an amount equal to its lost profits or a reasonable royalty on the infringing sales, or whichever measure of damages the court shall have applied, and COMPANY shall
pay to M.I.T. based upon such amount a reasonable approximation of the royalties and other amounts that COMPANY would have paid to M.I.T. if COMPANY had sold the infringing products, processes and services rather than the infringer, (iii) as to
special or punitive damages, the parties shall share equally in any award, and (iv) COMPANY shall receive all of any assessed attorneys fees and costs. 

7.6 Cooperation. Each party agrees to cooperate in any action under this Article which is controlled by the other party, provided that
the controlling party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance. 

7.7 Right to Sublicense. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in EXCLUSIVE FIELD ONE or EXCLUSIVE
FIELD TWO, as applicable under this Agreement, in the TERRITORY, COMPANY shall have the sole right to sublicense any alleged infringer in the EXCLUSIVE FIELD ONE or EXCLUSIVE FIELD TWO in the 

  
 15 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
TERRITORY for future use of the PATENT RIGHTS in accordance with the terms and conditions of this Agreement relating to sublicenses. Any upfront fees as part of such sublicense shall be shared
equally between COMPANY and M.I.T.; other revenues to COMPANY pursuant to such sublicense shall be treated as set forth in Article 4. 

8. INDEMNIFICATION AND INSURANCE. 

8.1 Indemnification. 

(a) Indemnity. COMPANY shall indemnify, defend, and hold harmless M.I.T. and its trustees, officers, faculty, students, employees, and
agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss, or expense (including reasonable attorneys’ fees and expenses) incurred by or imposed upon any of the Indemnitees in
connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to COMPANY’s exercise of any rights granted to COMPANY under this Agreement or any breach of this Agreement by COMPANY. 

(b) Procedures. The Indemnitees agree to provide COMPANY with prompt written notice of any claim, suit, action, demand, or judgment for
which indemnification is sought under this Agreement. COMPANY agrees, at its own expense, to provide attorneys reasonably acceptable to M.I.T. to defend against any such claim. The Indemnitees shall cooperate fully with COMPANY in such defense and
will permit COMPANY to conduct and control such defense and the disposition of such claim, suit, or action (including all decisions relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall have the right to
retain its own counsel, at the expense of COMPANY, if representation of such Indemnitee by the counsel retained by COMPANY would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party
represented by such counsel. COMPANY agrees to keep M.I.T. informed of the progress in the defense and disposition of such claim and to consult with M.I.T. with regard to any proposed settlement. 

8.2 Insurance. COMPANY shall obtain and carry in full force and effect commercial general liability insurance, including product
liability and errors and omissions insurance which shall protect COMPANY and Indemnitees with respect to events covered by Section 8.1(a) 

  
 16 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
above. Such insurance (i) shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by M.I.T., such approval not to be unreasonably
withheld, (ii) shall list M.I.T. as an additional insured thereunder, (iii) shall be endorsed to include product liability coverage, and (iv) shall require thirty (30) days written notice to be given to M.I.T. prior to any
cancellation or material change thereof. The limits of such insurance shall not be less than [***]. In the alternative, COMPANY may self-insure subject to prior approval of M.I.T., such approval shall not be unreasonably withheld. COMPANY shall
provide M.I.T. with Certificates of Insurance evidencing compliance with this Section. COMPANY shall continue to maintain such insurance or self-insurance after the expiration or termination of this Agreement during any period in which COMPANY or
any AFFILIATE or SUBLICENSEE continues (i) to make, use, or sell a product that was a LICENSED PRODUCT under this Agreement or (ii) to perform a service using a LICENSED PRODUCT, and thereafter for a period of five (5) years. 

9. NO REPRESENTATIONS OR WARRANTIES. 

EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE
PATENT RIGHTS OR [***] AND EACH PARTY HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS OF SUCH PARTY OR THIRD PARTIES, VALIDITY, ENFORCEABILITY AND SCOPE OF THE PATENT RIGHTS, WHETHER ISSUED OR PENDING, OR [***] AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. 

IN NO EVENT SHALL EITHER M.I.T., ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES OR COMPANY, ITS DIRECTORS, OFFICERS, EMPLOYEES
AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER M.I.T. OR COMPANY, AS APPLICABLE, SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 

  
 17 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 10. ASSIGNMENT. 

This Agreement is personal to COMPANY and no rights or obligations may be assigned by COMPANY without the prior written consent of M.I.T.
Notwithstanding the foregoing, COMPANY may assign this Agreement without the consent of M.I.T. in connection with the sale of all or substantially all of its assets (whether by merger, consolidation or otherwise); provided that the assignee shall
have agreed in writing assume all obligation hereof and to be bound by the terms and conditions hereof prior to such assignment. Failure of such assignee to so agree shall be grounds for termination by M.I.T. under Section 12.3. 

11. GENERAL COMPLIANCE WITH LAWS 

11.1 Compliance with Laws. COMPANY shall use reasonable commercial efforts to comply with all commercially material local, state,
federal, and international laws and regulations relating to the development, manufacture, use, and sale of LICENSED PRODUCTS. 
 11.2
Export Control. COMPANY and its AFFILIATES and SUBLICENSEES shall comply with all United States laws and regulations controlling the export of certain commodities and technical data, including without limitation all Export Administration
Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries. COMPANY hereby gives
written assurance that it will comply with, and will cause its AFFILIATES and SUBLICENSEES to comply with, all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by
itself or its AFFILIATES or SUBLICENSEES, and that it will indemnify, defend, and hold M.I.T. harmless (in accordance with Section 8.1) for the consequences of any such violation. 

11.3 Non-Use of M.I.T. Name. COMPANY and its AFFILIATES and SUBLICENSEES shall not use the name of “Massachusetts Institute of
Technology,” “Lincoln Laboratory” or any variation, adaptation, or abbreviation thereof, or of any of its trustees, officers, faculty, students, 

  
 18 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
employees, or agents, or any trademark owned by M.I.T., or any terms of this Agreement in any promotional material or other public announcement or disclosure without the prior written consent of
M.I.T, which consent M.I.T. may withhold in its sole discretion. The foregoing notwithstanding, without the consent of M.I.T., COMPANY may make factual statements during the term of this Agreement that COMPANY has a license from M.I.T. under one or
more of the patents and/or patent applications comprising the PATENT RIGHTS. 
 11.4 Marking of LICENSED PRODUCTS. To the extent
commercially feasible and consistent with prevailing business practices, COMPANY shall mark, and shall cause its AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS that are manufactured or sold under this Agreement with the number of each
issued patent under the PATENT RIGHTS that applies to such LICENSED PRODUCT. 
 12. TERMINATION. 

12.1 Voluntary Termination by COMPANY. COMPANY shall have the right to terminate this Agreement, for any reason, (i) upon at least
six (6) months prior written notice to M.I.T., such notice to state the date at least six (6) months in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to M.I.T. through such termination
effective date. 
 12.2 Cessation of Business. If COMPANY ceases to carry on its business related to this Agreement, M.I.T. shall
have the right to terminate this Agreement immediately upon written notice to COMPANY. 
 12.3 Termination for Default. 

(a) Nonpayment. In the event COMPANY fails to pay any amounts due and payable to M.I.T. hereunder, and fails to make such payments
within [***] after receiving written notice of such failure, M.I.T. may terminate this Agreement immediately upon written notice to COMPANY. 

  
 19 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 (b) Material Breach. In the event COMPANY commits a material breach of its obligations
under this Agreement, except for breach as described in Section 12.3(a), and fails to cure that breach within [***] after receiving written notice thereof, M.I.T. may terminate this Agreement immediately upon written notice to COMPANY. 

12.4 Termination as a Consequence of Patent Challenge. 

(a) By COMPANY. If COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against M.I.T., or assists others in bringing a PATENT
CHALLENGE against M.I.T. (except as required under a court order or subpoena), then M.I.T. may immediately terminate this Agreement. 
 (b)
By SUBLICENSEE. If a SUBLICENSEE brings a PATENT CHALLENGE or assists another party in bringing a PATENT CHALLENGE (except as required under a court order or subpoena), then M.I.T. may send a written demand to COMPANY to terminate such
sublicense. If COMPANY fails to so terminate such sublicense within [***] after M.I.T.’s demand, M.I.T. may immediately terminate this Agreement. 

12. 5 Disputes regarding Termination. If COMPANY disputes any termination by M.I.T. under this Section, it must notify M.I.T. of the
nature of such dispute and the proposed manner in which to resolve the dispute within [***] of receipt of notification of breach or notification of termination by M.I.T., whichever is sooner. If the parties do not resolve such dispute within [***]
of such notification, then COMPANY shall be required to initiate the dispute resolution procedures outlined in Section 13.3(a) within [***]. If it does not do so, COMPANY shall be considered to have waived its rights to dispute the termination.

  
 20 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 12.6 Effect of Termination. 

(a) Survival. The following provisions shall survive the expiration or termination of this Agreement: 

•     Article 1 (“Definitions”); 

•     Article 8 (“Indemnification and Insurance”); 

•     Article 9 (“No Representations or Warranties”); 

•     Article 13 (“Dispute Resolution”); 

•     Article 14 (“Miscellaneous”); 

•     Section 2.6(a) (“Grant from COMPANY to M.I.T”) 

•     Section 2.6(c) (“Rights in EXCLUSIVE FIELD TWO”) 

•     Section 5.2 (“Content of Reports and Payments”); 

•     Section 5.4 (“Records”); 

•     Section 11.1 (“Compliance With Laws”); 

•     Section 11.2 (“Export Control”); and 

•     Section 12.6 (“Effect of Termination”). 

(b) Pre-termination Obligations. In no event shall termination of this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the
obligation to pay any amounts that became due on or before the effective date of termination. 
 13. DISPUTE RESOLUTION. 

13.1 Mandatory Procedures. The parties agree that any dispute arising out of or relating to this Agreement shall be resolved solely by
means of the procedures set forth in this Article, and that such procedures constitute legally binding obligations that are an essential provision of this Agreement. If either party fails to observe the procedures of this Article, as may be modified
by their written agreement, the other party may bring an action for specific performance of these procedures in any court of competent jurisdiction. 

13.2 Equitable Remedies. Although the procedures specified in this Article are the sole and exclusive procedures for the resolution of
disputes arising out of or relating to this Agreement, either party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm to itself or to preserve
its rights under this Agreement. 

  
 21 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 13.3 Dispute Resolution Procedures. 

(a) Mediation. In the event of any dispute arising out of or relating to this Agreement, either party may initiate mediation upon
written notice to the other party (“Notice Date”) pursuant to Section 14.1, whereupon both parties shall be obligated to engage in a mediation proceeding. The mediation shall commence within [***] of the Notice Date. The mediation
shall be conducted by a single mediator in Boston, Massachusetts. The party requesting mediation shall designate two (2) or more nominees for mediator in its notice. The other party may accept one of the nominees or may designate its own
nominees by notice addressed to the American Arbitration Association (AAA) and copied to the requesting party. If within, fifteen (15) days following the request for mediation, the parties have not selected a mutually acceptable mediator, a
mediator shall be appointed by the AAA according to the Commercial Mediation Rules. The mediator shall attempt to facilitate a negotiated settlement of the dispute, but shall have no authority to impose any settlement terms on the parties. The
expenses of the mediation shall be borne equally by the parties, but each party shall be responsible for its own counsel fees and expenses. 

(b) Trial Without Jury. If the dispute is not resolved by mediation [***] days after commencement of mediation, each party shall have
the right to pursue any other remedies legally available to resolve the dispute, provided, however, that the parties expressly waive any right to a jury trial in any legal proceeding under this Article. 

13.4 Performance to Continue. Each party shall continue to perform its undisputed obligations under this Agreement pending final
resolution of any dispute arising out of or relating to this Agreement; provided, however, that a party may suspend performance of its undisputed obligations during any period in which the other party fails or refuses to perform its undisputed
obligations. Nothing in this Article is intended to relieve COMPANY from its obligation to make undisputed payments pursuant to Articles 4 and 6 of this Agreement. 

  
 22 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 13.5 Statute of Limitations. The parties agree that all applicable statutes of
limitation and time-based defenses (including, but not limited to, estoppel and laches) shall be tolled while the procedures set forth in Sections 13.3(a) are pending. The parties shall cooperate in taking any actions necessary to achieve this
result. 
 14. MISCELLANEOUS. 

14.1 Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement,
and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile
numbers of the parties: 
  

					
	 If to M.I.T.:
	 		 	Massachusetts Institute of Technology
		 		 	Technology Licensing Office, Room NE18-501
		 		 	One Cambridge Center, Kendall Square
		 		 	Cambridge, MA 02142-1601
		 		 	Attention: Director
		 		 	[***]
		 		 	[***]

  

			
	 If to COMPANY:
	 	Still River Systems, Inc
		 	300 Foster Street
		 	Littleton, MA 01460
		 	Attention: CEO
		 	[***]
		 	[***]

 If to COMPANY, notices regarding financial matters, including invoices: 

 

					
		 		 	Contact Name: Controller
		 		 	Department: Accounting
		 		 	Address: as above
		 		 	Tel: as above
		 		 	Fax: as above

  
 23 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 All notices under this Agreement shall be deemed effective upon receipt. A party may change
its contact information immediately upon written notice to the other party in the manner provided in this Section. 
 14.2 Governing
Law. This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in
accordance with the laws of the Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which
the patent shall have been granted. The state and federal courts having jurisdiction over Cambridge, MA, USA, provide the exclusive forum for any PATENT CHALLENGE and/or any court action between the parties relating to this Agreement. COMPANY
submits to the jurisdiction of such courts and waives any claim that such court lacks jurisdiction over COMPANY or its AFFILIATES or constitutes an inconvenient or improper forum. 

14.3 Force Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party,
including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement
with reasonable dispatch whenever such causes are removed. 
 14.4 Amendment and Waiver. This Agreement may be amended, supplemented,
or otherwise modified only by means of a written instrument signed by both parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights
or fail to act in any other instance, whether or not similar. 
 14.5 Severability. In the event that any provision of this Agreement
shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the parties shall negotiate in good faith to modify the Agreement to preserve (to the extent
possible) their original intent. If the parties fail to reach a modified agreement within thirty (30) days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the procedures set
forth in Article 13. While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the parties. 

  
 24 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 14.6 Binding Effect. This Agreement shall be binding upon and inure to the benefit of
the parties and their respective permitted successors and assigns. 
 14.7 Headings. All headings are for convenience only and shall
not affect the meaning of any provision of this Agreement. 
 14.8 Confidentiality. Each party hereto agrees that, except with the prior
written permission of the other party, it shall at all times hold in confidence and trust and not use or disclose Section 4 of this Agreement or any information marked “confidential” by a party that is provided to or learned by the
other party in connection with such other party’s rights under this Agreement; provided, however, each party may disclose any such information to the extent necessary (i) as required to comply with any applicable law or by any court or
other governmental body, provided that such party provides the other party with prompt notice of such court order or requirement to enable the other party to seek a protective order or otherwise to prevent or restrict such disclosure; (ii) to
legal counsel of such party; or (iii) in connection with the enforcement of this Agreement or rights under this Agreement. 
 14.9
Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements or understandings between the parties relating to its subject matter. 

  
 25 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly
authorized representatives. 
 The EFFECTIVE DATE of this Agreement is June 20, 2011. 

 

									
	 MASSACHUSETTS INSTITUTE OF

TECHNOLOGY
	 		 	STILL RIVER SYSTEMS, INC.
					
	By:	 	/s/ John H. Turner, Jr.	 		 	By:	 	/s/ Joseph Jachinowski
	Name:	 	John H. Turner, Jr.	 		 	Name:	 	Joseph Jachinowski
	Title:	 	 Associate Director, Technology Licensing Office
	 		 	Title:	 	CEO

  
 26 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 APPENDIX A 

List of Patent Applications and Patents 

[***] 

  
 27 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 APPENDIX B 

List of Countries (excluding United States) for which 

PATENT RIGHTS Applications Will Be Filed, Prosecuted and Maintained 

In Europe the following countries shall be designated: 
 United
Kingdom, France, Germany, and Italy 

  
 28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]